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Economic Impact of the Mass. Biomedical Industry 
 
Abstract 
Massachusetts Biomedical Initiatives (MBI) is a biomedical incubator. We assessed the 
economic impact of the Central Massachusetts and Boston-Worcester biomedical corridors and 
developed a 5-year forecast. Since 2004, the economic impact of the Central Massachusetts 
Biomedical industry grew 136% and today has a direct economic impact of $2.2 billion. The 
economic impact is expected to grow about 182% by 2012. The Boston-Worcester corridor 
currently has a direct economic impact of $8.8 billion.  
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Economic Impact of the Mass. Biomedical Industry 
Executive Summary 
 “Economic Impact of the Massachusetts Biomedical Industry” is an in depth study of the 
biomedical industry has done for Kevin O‟Sullivan of Massachusetts Biomedical Initiatives 
(MBI). MBI is a biomedical incubator located in Worcester, Massachusetts. It rents space, 
provides equipment, and offers services to startup biomedical companies as well as established 
companies wishing to start up a new division. It is MBI‟s mission to help these companies 
develop to a level where they can safely enter the market without a high risk of failure. By doing 
this, they hope to increase the number of jobs and economic contribution within the 
Massachusetts biomedical industry and consequently help foster its growth and development. 
 Massachusetts is one of the largest and most successful biomedical clusters in the world. 
Arguably, Massachusetts is second only to California and has been growing rapidly since its 
birth with Boston as its main hub. Other than Boston, Central Massachusetts has been one of the 
largest and fastest growing clusters in Massachusetts. The number of biomedical companies and 
employees in Central Massachusetts is getting close to the numbers in Boston, and is continuing 
to grow. Despite the success of these biomedical clusters and the Massachusetts biomedical 
industry as a whole, there are obstacles that threaten their continued growth. Many of these 
obstacles stem from the problems that the United States biomedical industry is currently facing. 
The United States has been the largest and strongest biomedical industry in the world but like 
Massachusetts, certain obstacles are threatening its continued growth and ranking within the 
global industry. By transference, Massachusetts and its clusters are feeling the effects of these 
obstacles as well as others unique to its own industry. 
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 This project has several of goals that address the above-mentioned issues. Its main goal 
was to determine the economic impact of the Central Massachusetts biomedical industry. Our 
sponsor, Kevin O‟Sullivan, established this as the central goal. From there we determined the 
economic impact of what we refer to as the Boston to Worcester Corridor and made comparisons 
between the clusters in which the corridor is made up of. The next goal was to benchmark the 
United States biomedical industry and finally, to forecast these industries based on their specific 
metrics. With these goals accomplished, we were able to determine the status of these industries, 
how well they will do in the future in face of their impeding obstacles, and what can be done to 
overcome or prevent these obstacles from deterring the Central Massachusetts and Massachusetts 
biomedical industry‟s growth. 
 Kevin O‟Sullivan and MBI plan to use this information as a tool to help foster the growth 
and development of the Massachusetts biomedical industry. They will present our findings to 
government officials and organizations, the media, colleges and universities, and organizations 
such as the Massachusetts Biotechnology Council (MBC) in hopes that it will inspire them to 
invest more in the industry. Also by doing this, they hope to attract more biomedical companies 
to Massachusetts and inspire students to do their studies in related fields and eventually join the 
industry. With increased amounts of funding, companies, jobs, and labor, the Massachusetts 
biomedical industry will hopefully be able to overcome many of its obstacles and grow to a level 
that can effectively compete with the largest biomedical industries in the world. 
 To determine the economic impact of the Central Massachusetts biomedical industry we 
first had to define the area it occupies in Massachusetts. Part of this study was done before in 
2004 by another MQP team here at WPI. They had defined Central Massachusetts as Worcester 
County. In order to keep the data consistent and to make comparisons, we used the same 
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definition. Using Worcester County as a basis, we made a list of the companies using sources 
such as the Mass High Tech Journal, MBC, and MacRae‟s Bluebook. We contacted these 
companies to find the number of employees and what the 2004 team called their FTE costs. FTE 
costs are the costs associated with one full time employee (e.g. salary, benefits, overhead, etc.). 
To find the economic impact of Worcester County we took the average FTE cost and multiplied 
it by the total number of employees in the region. This is once again based on the 2004 
methodology. 
 Based on the definition we received from Kevin O‟Sullivan, we defined the Boston – 
Worcester Corridor as Boston, Cambridge, Greater Boston, Worcester County, and other areas 
between route 2, 9, and 90. Using the same methodology as before, we found the economic 
impact of these different regions and added them together to get the economic impact of the 
corridor. We then did regional comparisons to determine the areas with the highest number of 
companies and employees in the biomedical industry. We also compared their economic impacts. 
We did this to determine the makeup of the Massachusetts biomedical industry. It was not done 
with the intent of showing that these regions are in competition with each other. We actually 
promote unity amongst the regions as opposed to creating competition. 
 To benchmark the United States biomedical industry, we organized our data using 
Porter‟s Competitive advantages. This was done in order to effectively see the strengths and 
weaknesses of the different industries. We compared the United States with Europe and the Asia 
Pacific industries. We focused only on China and India for the Asia Pacific industry because 
those are the largest and fastest growing industries in that region. A lot of the information came 
from a report done by Ernst & Young which is a trusted source for market and industry data. The 
rest of the data came from individual case studies on the different regions. 
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 To forecast the Central Massachusetts biomedical industry, we used a simple linear 
equation along with compounding. We found the average growth rate for the number of 
companies, employees, and economic impact, and extended it to five years using a compounding 
equation. We did the same for the Massachusetts industry. Knowing that this process is highly 
unreliable and produces inaccurate projections, we incorporated qualitative data and adjusted the 
growth rates based on it. The qualitative data came from case studies and expert opinions which 
we obtained through interviews. We also did a SWOT analysis of the individual industries to 
help determine their actual projected growth. 
 Due to a lack of information, we did not forecast the United States biomedical industry in 
the same manner. We used all qualitative data as opposed to quantitative in order to forecast the 
United States industry. We did however use the SWOT analysis in the same manner as before. 
We did a SWOT analysis for the United States, Europe, and the Asia Pacific region to help 
determine the future of the United States biomedical industry. 
 The Central Massachusetts biomedical industry has a direct economic impact of $2.2 
billion and has grown 136 percent since 2004. We expect it to grow to $6.1 billion by 2012, 
which is a 182 percent increase.  It has a total of 162 companies and 16,441 employees and is 
expected to grow to 270 companies and 47,743 employees in 2012. That is a 67 percent and 159 
percent  increase in growth respectively. Massachusetts has approximately 1,150 biomedical 
companies and 102,586 employees. We could not accurately predict the number of companies in 
Massachusetts for 2012 because the original growth rate was negative. We do however believe 
that the number will increase substantially. The number of employees will increase to about 
210,446 in 2012, which is a growth of 105 percent. 
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 The United States biomedical industry continues to be the largest and strongest in the 
world. Based on Porter‟s Competitive Advantages and the SWOT analysis we did their dominant 
presence in the global industry may not continue. With several governmental policies hindering 
growth in the United States biomedical industry and creating rapid growth in both China and 
India; it would not be surprising to see transference in power in the near future. Due to China‟s 
new governmental policies in funding, patent laws, drug development, trade, and tax incentives; 
it has seen substantial growth and if fact has the highest growth rate in the biomedical industry. 
The United States policies in these areas have done just the opposite and if they are not dealt 
with in the near future, there is a possibility of China becoming the largest biomedical industry. 
 As mentioned before, the majority of the problems Massachusetts and Central 
Massachusetts are facing today stem for the problems of the United States biomedical industry. 
In order to create more growth and maintain its dominance within the global industry, the United 
States needs to change several of its policies. It needs to increase its funding through programs 
such as NIH grants. It needs to create more appealing tax and trade incentives. It needs to 
increase funding to education especially for K-12 science education. Patent laws need to become 
more lenient in order to encourage the development of new drugs and products. Also, the 
government needs to take a more hands off stance on regulating drug and biomedical device 
prices. 
 
 
 
 
 9 
Table of Contents 
 
ABSTRACT……………………………………………………………………..……………….2 
ACKNOWLEDGEMENTS ......................................................................................................... 3 
EXECUTIVE SUMMARY .......................................................................................................... 4 
1.0 - INTRODUCTION.………………………………………………………………………..15 
2.0 – BACKGROUND ................................................................................................................ 18 
2.1 - Incubator Industry ............................................................................................................. 18 
2.2 - Massachusetts Biomedical Initiatives ............................................................................... 19 
2.3 – Global Biomedical Industry .............................................................................................. 20 
2.3.1 – Porter’s Competitive Advantages .................................................................................. 25 
2.3.2 - Regional Profiles .............................................................................................................. 26 
2.3.2.1 - Asia-Pacific .................................................................................................................... 26 
2.3.2.2 – Europe ........................................................................................................................... 28 
2.3.2.3 – America ......................................................................................................................... 28 
2.3.3 - Government Incentives & Involvement ......................................................................... 29 
2.3.3.1 – China ............................................................................................................................. 29 
2.3.3.2 – India .............................................................................................................................. 31 
2.3.3.3 – Europe ........................................................................................................................... 31 
2.3.3.4 – America ......................................................................................................................... 32 
2.3.4 - Research Institutes & Incubators .................................................................................. 33 
2.3.4.1 – China ............................................................................................................................. 33 
2.3.5.2 – America ......................................................................................................................... 34 
2.3.5 - Education .......................................................................................................................... 35 
2.3.5.1 - China & India ............................................................................................................... 35 
 10 
2.3.5.2 – America ......................................................................................................................... 36 
2.3.6 - Outsourcing and Globalization ...................................................................................... 36 
2.3.6.1 – China ............................................................................................................................. 36 
2.3.6.2 – India .............................................................................................................................. 37 
2.3.6.3 – Europe ........................................................................................................................... 39 
2.4 – Regional Industry............................................................................................................... 40 
2.4.1 – Colleges of Worcester Consortium (COWC) ............................................................... 40 
2.5 – Benchmarking .................................................................................................................... 42 
2.6 - Forecasting .......................................................................................................................... 45 
3.0 – METHODOLOGY ............................................................................................................ 48 
3.1 - Determining the Economic Impact of Central Massachusetts .......................................... 48 
3.1.1 – Boston – Worcester Corridor and Other Regions ....................................................... 49 
3.2 – Benchmarking the Massachusetts Biomedical Industry and Beyond ........................... 50 
3.3 - Impact of the COWC ......................................................................................................... 51 
3.4 - Forecasting .......................................................................................................................... 52 
3.5 - Market Research................................................................................................................. 53 
3.5.1 - Analysis ............................................................................................................................. 53 
4.0 – ANALYSIS ......................................................................................................................... 55 
4.1 – Economic Impact of Central Massachusetts ................................................................... 55 
4.1.1 – Benchmark of the Central Mass Biomedical Industry ................................................ 56 
4.2 – Economic Impact of the other Massachusetts Regions .................................................. 59 
4.2.1 – Boston & Greater Boston ............................................................................................... 59 
4.2.2 - Boston - Worcester Corridor .......................................................................................... 60 
4.2.3 – North Shore ..................................................................................................................... 60 
4.3 – Regional Comparisons ....................................................................................................... 61 
 11 
4.4 – Benchmark of the Massachusetts Biomedical Industry ................................................. 65 
4.4.1 - Massachusetts Biomedical Industry Past and Present ................................................. 65 
4.4.2 - State Comparisons ........................................................................................................... 67 
4.4.2.1 - Funding .......................................................................................................................... 67 
4.4.2.2 – Employment.................................................................................................................. 70 
4.4.2.3 Education ......................................................................................................................... 71 
4.4.2.4 - Biotechnology ................................................................................................................ 72 
4.4.3 - Global Biotechnology Industry....................................................................................... 75 
4.4.3.1 - Financial & Economic Metrics .................................................................................... 76 
4.4.3.2 – Educational Metrics and Patents ................................................................................ 78 
4.4.3.3 – Global Alliances ........................................................................................................... 80 
4.5 - Forecasting .......................................................................................................................... 81 
4.5.1 – Central Massachusetts .................................................................................................... 82 
4.5.2 – Massachusetts .................................................................................................................. 84 
4.6 – SWOT Analysis .................................................................................................................. 85 
4.6.1 – Central Massachusetts .................................................................................................... 86 
4.6.2 – Massachusetts .................................................................................................................. 86 
4.6.3 – Global ............................................................................................................................... 87 
4.6.3.1 – America ......................................................................................................................... 87 
4.6.3.2 – Europe ........................................................................................................................... 88 
4.6.3.3 – Asia Pacific ................................................................................................................... 89 
4.7 – Forecasting Justification ................................................................................................... 90 
4.7.1 – Central Massachusetts. ................................................................................................... 92 
4.7.2 – Massachusetts. ................................................................................................................. 93 
5.0 – CONCLUSIONS AND RECOMMENDATIONS ........................................................... 95 
 12 
5.1 – Forecasting Conclusions .................................................................................................... 95 
5.1.1 – Central Massachusetts .................................................................................................... 95 
5.1.2 – Massachusetts .................................................................................................................. 98 
5.1.3 – America ............................................................................................................................ 98 
5.2 – Recommendations ............................................................................................................ 100 
BIBLOGRAPHY....................................................................................................................... 101 
Appendix A: Central Massachusetts ....................................................................................... 104 
Appendix B: North Shore area ................................................................................................ 106 
 Appendix C: Biomedical Companies in Worcester County ……………………………….108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
Table of Figures 
 
Figure 1: Colleges of the Worcester Consortium ..................................................................... 41 
Figure 2: FTE cost in Central Mass .......................................................................................... 57 
Figure 3: Economic Impact in Central Mass ........................................................................... 57 
Figure 4: Central Mass Employees ........................................................................................... 58 
Figure 5: Central Mass Companies ........................................................................................... 59 
Figure 6: Regional Comparisons (Companies) ........................................................................ 61 
Figure 7: Regional Comparisons (Employees) ......................................................................... 62 
Figure 8: Major Areas Company Comparison ........................................................................ 63 
Figure 9: Major Areas Employee Comparison ........................................................................ 63 
Figure 10: Economic Impact Comparison ................................................................................ 64 
Figure 11: Massachusetts Employees ........................................................................................ 66 
Figure 12: Massachusetts Companies ....................................................................................... 67 
Figure 13: NIH Funding & Grantee.......................................................................................... 68 
Figure 14: Venture Capital ........................................................................................................ 70 
Figure 15: Life Sciences Employment ....................................................................................... 71 
Figure 16: Life Sciences PhDs .................................................................................................... 72 
Figure 17: Financial Highlights of U.S. Biotech Company ..................................................... 74 
Figure 18: Growth in Global Biotech ........................................................................................ 76 
Figure 19: Global Biotech at a Glance ...................................................................................... 77 
Figure 20: U.S. and Europe Financial ....................................................................................... 78 
Figure 21: Scientific Competitiveness ....................................................................................... 79 
Figure 22: Alliances by Regions................................................................................................. 81 
Figure 23: Forecasted Central Mass Companies ..................................................................... 82 
 14 
Figure 24: Forecasted Central Mass Employees ...................................................................... 83 
Figure 25: Forecasted Central Mass Economic Impact .......................................................... 83 
Figure 26: Forecasted Mass Companies ................................................................................... 84 
Figure 27: Forecasted Mass Employees .................................................................................... 85 
Figure 28: Central Mass Companies (Adjustment) ................................................................. 92 
Figure 29: Central Mass Employees (Adjustment).................................................................. 92 
Figure 30: Central Mass Economic Impact (Adjustment) ...................................................... 93 
Figure 31: Mass Employees (Adjustment) ................................................................................ 94 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                               
 15 
Economic Impact of the Mass. Biomedical Industry 
 
1.0 – Introduction 
Massachusetts Biomedical Initiatives (MBI) is a biomedical incubator whose goal is to 
help the central Massachusetts life science industry to grow and prosper by creating a 
collaboration of academia, entrepreneurs and venture capitalists. It achieves this goal by 
encouraging the commercialization of biomedical research in order to develop new 
biotechnology, medical devices, and pharmaceutical companies. MBI leases space and research 
equipment to entrepreneurs and large biomedical companies who wish to expand. These 
companies use MBI‟s facilities to start their operations and become established within the 
market. When they achieve this goal, they move on from MBI and set up their own facilities. 
MBI gives these companies the space, equipment, and services they need so that they can 
prosper in the market, which in turn helps stimulate the biomedical industry and attract new 
business. The companies in return pay fees on top of the rent for leasing the space. They pay a 
gross yearly fee, common area usage, services/maintenance, utilities, and a one percent equity 
agreement. 
There are two main objectives this project will achieve. The first objective is to determine 
the economic impact of the Central Massachusetts and Boston – Worcester biomedical corridor. 
The second objective is to forecast the Central Massachusetts biomedical industry five years 
from now. There are several additional goals this project will achieve based on the two main 
objectives. It will determine the economic impact of other regions in Massachusetts including the 
Boston area and the North Shore, compare these regions to determine the percentage breakdown 
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of the Massachusetts biomedical industry, and then follow the same process to examine the 
industry on a statewide, national, and global level. 
MBI‟s primary objective with this project is to evaluate the biomedical industry on a 
regional, national and global scale. MBI plans to achieve several objectives with this 
information. Firstly, they will use it as a tool for themselves by taking advantage of early 
warning signs for both good and bad changes in the biomedical industry. MBI will analyze the 
quantitative and qualitative trends showing where the Massachusetts biomedical industry is 
going. MBI, along with other institutions both governmental and private, will then make plans to 
either find ways of driving the industry forward or to take advantage of its growing progress. 
Secondly, they will provide the media with the evaluations in order to educate the public, 
industry, government, and educational institutions in hope that it will help build momentum and 
support for the industry. They also plan to use this information to show organizations such as the 
Massachusetts Biotech Council (MBC) and Massachusetts Medical Device Industry Council 
(MassMedic) whose goal is to support the biomedical industry and to ensure that the industry 
worthwhile to invest. Thirdly, if the research shows that the biomedical industry of 
Massachusetts is growing, MBI will use that research to convince organizations such as these as 
well as governmental agencies that it will be profitable for them and the state of Massachusetts to 
invest in the industry. Last but not least, some additional goals MBI wishes to achieve are to 
update their own biomedical state of the industry report, to evaluate the state of the industry in 
Massachusetts within a global environment, and to evaluate the trends of college consortiums. 
In order to provide MBI with this information, benchmarking and forecasting methods 
must be used. Using market analysis reports, case studies, and other relevant resources, our team 
can benchmark the biomedical and life science industry on a regional (Worcester to Boston 
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“Corridor”), statewide, national, and global level for the year 2007. The research will be both 
qualitative (e.g., the emergence of life science facilities within the Colleges of Worcester 
Consortium [COWC]) and quantitative (e.g., statistics regarding the number of life science 
businesses that have emerged in the past five years) in nature. Using forecasting techniques, we 
will be able to make predictions about the direction this industry will be going five years from 
now. Important topics of research such as college consortiums, government policies, market 
analysis, and industry funding will be included to provide MBI with the above-mentioned 
information. The team will also evaluate other information such as the operations and policies 
practiced by biomedical industries in other countries, which could be applicable to the 
Massachusetts biomedical industry. It will also give basic information on the industry starting on 
a regional level and working its way up to the global industry. 
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2.0 – Background 
 The purpose of our project was to analyze the biomedical industry on different 
geographic levels by developing and utilizing a benchmarking system.  Through the use of our 
benchmarks, we were able to evaluate the state of the Central Massachusetts biomedical industry 
and the economic impact it has on the state, determine the standing of the Massachusetts 
biomedical industry compared to other top biomedical states, determine America‟s status in the 
world‟s biomedical industry, and forecast the state of the industry on these three levels within the 
next five years. The following chapter will outline the importance of this study and how MBI and 
other biomedical incubators play a vital role in supporting the biomedical industry. 
 
2.1 - Incubator Industry 
 The business incubator industry has been around since 1959 and has become an 
organized and necessary tool for startup companies.  The National Business Incubation 
Association (NBIA), which was founded in 1985, defines business incubation as “a business 
support process that accelerates the successful development of start-up and fledgling companies 
by providing entrepreneurs with an array of targeted resources and services” (NBIA).  Simply 
put, a business incubator provides the technology and resources necessary to start a company.  
Common resources that an incubator may make available to its entrepreneurs are materials and 
equipment. In the case of a biomedical incubator, this could include emergency chemical washes, 
lab space, refrigeration units or chemical exhaust hoods (NBIA).   
 Business incubators are responsible for starting a growth trend among the areas of study 
they house.  The companies, which ideally run independently of the incubator, have an 
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interesting effect on local life including job production and a local interest in different fields of 
study.  For example, MBI has joined the industry by providing biomedical incubation facilities 
which greatly increase the appeal of Worcester as a location to incubate or start a new life 
sciences related company. Additionally, the increase in jobs can help stimulate the local 
economy in the simplest way, since so much work needs to be done in such small facilities. 
 Another positive effect incubation can have on local and regional economies are 
government subsidies, which are provided by the government to continue stimulating local 
economies.  NBIA reports that for every $1 provided in government subsidies to an incubator, 
$30 of tax revenue is produced.  Additionally, studies have shown that 84 percent of incubator 
graduates remain in their community and stimulate the economy even further (NBIA).  MBI 
currently hosts startup companies in three different Worcester locations. This gives a lot of 
exposure to the community of their existence as well as the potential for more companies to start 
and stay in the Worcester area. 
 
2.2 - Massachusetts Biomedical Initiatives 
 MBI centered in the public‟s eyes in 1985 when its Worcester Board of Trustees decided 
to develop and implement a plan to create public/private partnerships in the community for 
boosting economic and life science development in Worcester.  Through the use of the 
partnerships, MBI has succeeded in creating and maintaining its three incubator facilities in 
Worcester to help create “unique life sciences commercialization centers” (MBI). 
 MBI‟s mission is to “commercialize science”.  Their only purpose to facilitate the 
development and advancement of life science and biomedical device companies in the region is 
 20 
to create jobs and facilitate economic development.  Their ultimate goal is to fully develop 
Massachusetts‟ biomedical industry by providing fully equipped and maintained facilities for its 
tenants for flat rental prices (MBI).  Our goal was to discuss the different regions of development 
for biomedical incubators and to see how MBI can benefit from the information gathered to 
make their company more appealing and a better player in the incubator industry. 
 
2.3 – Global Biomedical Industry 
Between the years 2005 and 2006 the global biotechnology industry has grown 14 
percent in revenues, there was a 33 percent increase in R&D expenses, a 35 percent increase in 
net losses, a 10 percent increase in the number of employees and a 0.3 percent increase in the 
number of public and private companies. (Ernst & Young, pg.8) It is safe to say that the global 
biotechnology industry is continuing to grow at a rapid pace however; it would be a mistake to 
overlook the growing problems that have hindered the industry‟s growth. It is without a doubt 
that governmental, cross-border, cultural, and globalization issues have negatively affected the 
growth of the biotechnology industry. In this expanding industry and in the midst of these 
growing issues, America, Europe, and the Asia-Pacific region have become the largest players in 
the continuing effort to promote continued growth in the biomedical industry. Continuing strides 
made by these regions of the world, in achieving competitive advantage, is what has created this 
industries continuing success and will continue to do so in the future.  
There are several factors, which both small and large companies in America, Europe, the 
Asia-Pacific region, as well as other countries have supported, that have contributed to the level 
of success the global biotechnology industry has recently experienced. The contribution levels of 
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each region will be discussed in further detail later on in this section. Large companies for the 
most part have contributed the most to the success of the global biotechnology industry but that 
is not to say that small startup companies have not largely supported its growth. In 2006, public 
and private equity investors increased total capital by 42 percent and venture capital reached an 
all time record of $5.4 billion. Venture capital grew by 38 percent in the U.S. and 47 percent in 
Europe. Large pharmaceutical companies contributed to the rest of the growth in capital. What is 
interesting to notice is that even the large pharmaceutical companies are restructuring their 
departments to be more flexible and innovative just as the small biotech companies are. (Ernst & 
Young, pgs.7-8) 
One factor that greatly contributed to the global biotechnology industry‟s growth last year 
was the increased level of deals, alliances, partnerships, and mergers and acquisitions occurring 
throughout the world. Many happened within individual countries or regions such as Europe. 
Although benefits and growth are directly seen within the individual country or region, their 
achievements add on to the overall success of the global industry. Deals, merges, alliances, and 
partnerships are particular areas create what are known as pipelines and business clusters. These 
are a group of businesses that work together to gain financial support and success by sharing 
products, information, and equity to either create a particular product or to simply create all 
around growth and advancement. This trend in companies making deals is expected to increase 
within the next two years, which will create an even stronger global biotechnology industry. 52 
percent of the companies who plan to market new products said that they will do it with the help 
of alliance partners and 99 percent of American biotech companies and 87 percent European 
companies are planning to make deals within the next two years. The majority of the companies 
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in this study said assistance in sales and marketing was their primary reason for entering 
alliances and access to capital as a close second. (Ernst & Young, pgs.9-10) 
A study by Ernst and Young including over 400 companies showed that 66 percent of 
American companies and 76 percent of European companies said that they are planning to 
expand global operations (Ernst & Young). Deals made between companies in different 
countries or regions result in another factor that has helped create growth in the global industry. 
The sharing of information, products, equity, etc. through the creation of deals, alliances, 
mergers, and partnerships has created a level of globalization within the biotechnology industry. 
Although globalization is typically seen as a bad thing and has produced some negative effects 
for the biotechnology industry, it has benefited the growth of many countries‟ industries. By 
sharing things such as information and products and giving each other financial support through 
funding, biotech companies have been able to make great strides in creating new and innovative 
drugs as well as new strategies and procedures to cut costs and create more efficient ways of 
production. Globally, there has been a stronger focus on R&D and creating new products. The 
sharing of information and resources is essential in making a successful R&D and service 
oriented global biotech industry and the effects of globalization have assisted in this endeavor 
(Ernst & Young). 
Globalization has also produced some negative effects for the biotechnology industry. 
There are the common problems of the exploitation of workers, taking business out of countries, 
the different governmental policies and regulations, etc. Besides the typical list of problems 
associated with globalization, some others are more specific to the biotechnology industry. One 
problem it has created is cross-border agreements that are currently being argued over. Topics 
such as tax incentives and restrictions have been large debates, especially in Europe, in the past 
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few years and continue to be so. (Ernst & Young, pg.66) Another problem is that small 
companies have trouble in gaining competitive advantage. With mergers and alliances becoming 
more and more common, companies are focusing more on cooperating with each other making a 
more unified biotech industry, which makes it harder for small companies to gain competitive 
advantage and succeed in the market. It is in the opinion of Michael Porter that mergers and 
alliances for the sake of globalization “undermine the creation of competitive advantage” and 
that “Real national competitiveness requires governments to disallow mergers, acquisitions, and 
alliances that involve industry leaders.” (Porter, pg.19) 
Another factor that has contributed to the growth of the global biotechnology industry is 
the growing industries in China and India. These countries have been rapidly expanding in the 
last decade and have even been predicted to become the leaders in the biotech market. Factors 
such as large increases in a knowledgeable workforce, product patents, a push for a more R&D 
and service oriented industry, as well as several other factors, have created not just created 
growth in the biotech industry in China and India but the world as a whole as well. These factors 
have also been consistent issues for the biotechnology industry in the sense that it has been 
lacking a knowledgeable workforce, patent rights, etc. in past years. This topic will be further 
discussed in the following sections.  
As has been discussed throughout this section, there are some problems that the global 
biotechnology industry has been facing which has hindered its growth to a certain degree. One of 
the largest problems the industry faces is the “fourth hurdle” which health and safety agencies in 
many countries have been enforcing. The „fourth hurdle” is the evaluation of the cost-
effectiveness of new products (Ernst & Young). Lately, medical products, mainly drugs, have 
become too expensive for the common people to buy. Agencies such as the National Institute for 
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Health and Clinical Excellence in the U.K., as a result have been making price limits for the 
drugs manufactured by both large and small pharmaceutical companies. (Ernst & Young, pgs.2-
3) 
According to the Beyond Borders Global Biotechnology Report 2007 created by Ernst 
and Young, even though this issue is “often characterized as a debate about the price of drugs 
and the cost of health care, the core issue is really a broader one – innovation, and our 
willingness to pay for it.”(Ernst & Young) While government agencies are concerned about the 
price of the drugs being sold to the public, companies argue that they cannot continue operations 
without making up for the large costs of producing those drugs. This issue has been a growing 
concern for companies, the global industry, and the governments of several countries and even 
though governments encourage innovation and the production of new drugs, they are not willing 
to pay high costs for them. (Ernst & Young, pg.4) An increase in elderly people has made this 
issue even worse because drugs and health care increase with the age of the population, which 
causes drug prices to go up. (Ernst & Young, pg.3) 
The global biomedical industry has been growing steadily since its existence and has 
achieved a higher level of growth this year, than any other year in history except for 2002. This 
is not to say however, that it does not currently face problems that have hurt its growth. America, 
Europe and the Asia-Pacific region are the three main regions have contributed to this growth 
and have been facing these problems and each one is constantly looking to gain and maintain 
competitive advantage. The following sections are the descriptions of selected country and 
regions, with focus on their biotechnology industries and their areas of competitive advantages in 
the world market. 
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2.3.1 – Porter’s Competitive Advantages 
 The following sections on the global biomedical industry are divided into parts based on 
what Michael Porter considers to be a nation‟s competitive advantages.  This strategy was used 
to more clearly show the impact and advantages the industry has in each country discussed. 
There are four different attributes of national competitive advantage. There are the factor 
conditions, demand conditions, related and supporting industries, and firm strategy, structure, 
and rivalry. (Porter, p.78) 
 Factor conditions relates to “The nation‟s position in factors of production, such as 
skilled labor or infrastructure, necessary to compete in a given industry.” Porter states, 
“According to standard economic theory, factors of production – labor, land, natural resources, 
capital, and infrastructure – will determine the flow of trade.”(Porter, p.79) With the biomedical 
industry, resources such as an educated, skilled labor force, metals, technology, etc. would be 
considered beneficial factor conditions.  
Demand conditions relates to the amount of demand present within the companies home 
country. Porter believes that “Nations gain competitive advantage in industries where the home 
demand gives their companies a clearer or earlier picture of emerging buyer needs, and where 
demanding buyers‟ pressure companies to innovate faster and achieve more sophisticated 
competitive advantages than their foreign rivals.”(Porter, p.82) High age populations would be a 
large factor in the level of demand in a particular country for the biomedical industry.  
Having related and supporting industries gives companies access to pertinent resources 
and provides them with new technologies and other forms of innovation (Porter). The presence 
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of high tech zones and business incubators would be considered competitive advantages of a 
country for the biomedical industry.  
The firm‟s strategy, structure, and rivalry pertain largely to the countries culture and 
government. “National circumstances and context create strong tendencies in how companies are 
created, organized, and managed, as well as what the nature of domestic rivalry will be”(Porter, 
p.83).  To compete on a national level, government policies, laws, and funding need to be strong 
and favorable towards the development of a prominent biomedical industry. This includes topics 
such as patent laws, drug development policies, trade laws, funding, etc.  Beyond that, Porter 
states that the government has many roles and obligations in the development of creating 
competitive advantages. They need to “focus on specialized factor creation” (e.g. education & 
health care), “enforce strict product, safety, and environmental standards”, “sharply limit direct 
cooperation among industry rivals”, “avoid intervening in factor and currency markets”, 
“promote goals that lead to sustained investment”, “Deregulate competition”, “enforce strong 
domestic antitrust policies”, and “reject managed trade”(Porter, pp.87-89). 
 
2.3.2 - Regional Profiles 
2.3.2.1 - Asia-Pacific 
The biomedical industry in the Asia-Pacific region has been rapidly expanding over the 
past decade or so. Last year its revenues increased by 10 percent, its R&D expenses went up by 
28%, and the number of companies has increased by 4 percent. (Ernst & Young, pg.69) China 
and Indian are arguably the two main contributing factors to the region‟s growing success. Ever 
since their initiation into the World Trade Organization (WTO), China and Indian have made 
great strides to compete globally and become attractive areas to foreign investors (Liu & 
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Lundin). Within the past decade, certain fields of the region‟s biomedical industry have exceeded 
many of the top foreign countries and have been predicted to become one of the strongest and 
most prosperous in the coming ages. These predictions are predominantly based on their current 
growth rate within the market. For the past few years, China and India, China being stronger, 
have had the highest biomedical industry growth rate in the world (Ernst & Young).  
Even though their biomedical industry is rapidly growing, it is still low in market share in 
the global market. The market shares of their biomedical products are low in the global market 
and their expenditures R&D, which is arguably an essential part of the biomedical industry, are 
also comparatively low. Despite the Asia-Pacific region‟s currently low market share in the 
global biotechnology industry, their rapid growth in the industry has obtained great attention and 
demonstrates their potential of becoming a dominating player in the global biomedical market. 
China and India have shared several of the same attributes of success as well as growth 
trends in their biotechnology industries. Both industries started of as mainly manufacturing based 
due to the ease of creating cheap knock of drugs, created by the lack of intellectual property 
rights. Today they are both restructuring their industries to be more R&D and service-oriented 
and are seeing a lot of success because of their efforts. One of the reasons why they have seen 
success in this area is their hold on particular niches. China and India have a strong hold on the 
stem cell, gene therapy, and traditional medicinal systems mainly because of the regulations set 
by western governments on their own industries. They also have the advantage of cost-
effectiveness and cheap labor, which has made them attractive to foreign involvement. (Ernst & 
Young, pgs.69-71) 
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2.3.2.2 – Europe 
The European biotechnology industry has stayed at a steady and stable pace during the 
2005-2006 year. Its revenues have gone up by 13 percent, which more than made up for its loss 
in 2003, its R&D expenses went up by 8 percent, the number of employees went up by 11 
percent and its net loss has significantly gone down by negative 23 percent. Most of the 
industry‟s growth is contributed to large companies whom made up for approximately 80 percent 
of public company revenues. Europe, like the Asia-Pacific region, has a strong focus on R&D. 
32 percent of public company revenues and 67 percent of private company revenues account for 
R&D expenditures. Much of Europe‟s biotechnology industry‟s success can be attributed to the 
high levels of financing, the increase in percentage of the products developed, which was at 30 
percent, and the large number of deals, alliances, and mergers and acquisitions. (Ernst & Young, 
pgs.45-47) 
 
2.3.2.3 – America 
America currently has the largest biopharmaceutical market in the world with many of its 
drugs being developed due to biotechnology. It has more than 300 public biotechnology 
companies which employs over 130,000 people and represents $400 billion in market 
capitalization (Ernst & Young). It has remained the leader in the global biotechnology industry‟s 
revenues, profits, and jobs. Continuing with its current trend, the American biotechnology 
industry has substantially grown in the last year. Revenues grew by 13.4 percent, sales grew by 
13.4 percent, R&D expenses increased by 30.2 percent, the net loss increased by 58.5 percent 
and employment increased by 6 percent (Ernst & Young). These numbers are accurate although 
deceiving. The industry‟s net loss was 58.5 percent, which would commonly indicate a rough 
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year for the industry, but this was mainly due to two large acquisitions made that year (Ernst & 
Young). If these acquisitions had not occurred then the industry total revenues would have 
increased by 20 percent, the net loss would not have been so high and most importantly, the 
biotechnology industry would have been profitable for the first time in 31 years (Ernst & 
Young). Considering this, the American biotechnology industry did considerably well last year. 
However, it goes without saying that the industry faced several issues and roadblocks throughout 
the year and is continuing to do so.  
 
2.3.3 - Government Incentives & Involvement 
2.3.3.1 – China 
The Chinese government has been an integral contributor to the growth of biomedical 
industry and has been a supporter of it for many years now. Originally China‟s biomedical 
industry was heavily based on manufacturing and has seen a lot of success because of it. It has 
been predicted that the top biomedical companies of the world will have lost around 80 percent 
of their market due to generic competition. The majority of China‟s domestic products happen to 
be imitation/generic drugs as well as Traditional Chinese Medicine (TCM). The reason for the 
high production of imitation drugs is mainly contributed to the lack of sufficient ownership rights 
such as patents. This subject will be discussed further later on. (Liu & Lundin, pg.7) 
Even though manufacturing is the backbone of their biomedical industry and has seen 
great success; in the past few years the government has made great strides to change the industry 
from manufacturing to R&D by changing what they refer to as the national innovation system as 
well as joining the WTO. They believe that this will improve the biomedical industry by 
attracting foreign investment, creating opportunities for the development of new products, and by 
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adding an essential part of the industry that had been lacking in the past. The national innovation 
system consists of providing R&D with funding through grants and subsidies, and research 
institutions, government incentive programs, and contributions to higher education. (Liu & 
Lundin, pg.4) The Chinese government is also currently carrying out its eleventh five-year plan 
which increases biotech funding in several areas including screening for genetic diseases, 
developing biotech-based drugs and vaccines that are currently relevant to the diseases in China 
and increasing contract research services. (Ernst & Young, pg.77) 
The government has also been increasing its regulations and policies, mainly with focus 
on safety. In April of 2006 the government announced its recognition of the State Food and Drug 
Administration with the intent of preventing fraud, improving the drug approval process and 
prohibiting companies from using old products and selling it under different names. Also 
pertaining to safety, the government plans to “monitor drug companies, establish drug safety and 
review centers, and improve post-marketing surveillance.” (Ernst & Young, pg. 77) The Chinese 
government has also made efforts to improve manufacturing and intellectual property rights. It 
imposed the Good Manufacturing Practice requirements, which is intended to improve 
manufacturing quality and help consolidate the domestic industry. (Ernst & Young, pg. 77) 
In the past China has been know for not having strict intellectual property rights but now 
they have been making strides to change this through an increase in patents and other forms of 
protection. Ernst & Young did a study of the level of intellectual property rights by recording the 
amount of scientific paper citations, biotechnology patent applications, high school proficiency 
and the share of global biotechnology patents of several countries. The U.S., Japan, and some 
European countries such as the U.K. and Germany, were the top countries in scientific paper 
citations and the share of global biotechnology patents, which measures the growth of the 
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industry‟s current and past strengths in science and R&D. China and India however were the 
leaders in the high school proficiency rank and the growth in biotechnology patent applications, 
which measures the growth trends and investments in the future. (Ernst & Young, pg.6) 
 
2.3.3.2 – India 
The Indian government has made great efforts to help the biotechnology industry prosper. 
As mentioned before, the government has instituted stricter policies and regulations regarding 
intellectual property rights. In 2005, policymakers instituted the Indian Patent Act which allowed 
the patenting of pharmaceuticals for the first time. A strong push is currently being made for the 
institution of the National Biotechnology Development strategy which would promote 
innovation in smaller companies in several ways. A single National Biotechnology Regulatory 
Authority would provide faster and more efficient clearance of biotech products and would allow 
for faster foreign direct investment. Also, the government plans to support the creation of Special 
Economic Zones which are biotech parks. Currently there are only 5 parks in India. The parks 
are intended to create business cluster including companies, universities, and R&D institutes. 
(Ernst & Young, pg.79) 
 
2.3.3.3 – Europe 
European governments are trying to promote the biotechnology industry in three main 
ways two of which are funding incentives and the other tax incentives. The Seventh Framework 
Program for Research and Technological Development (FP7) and state aid for Young Innovative 
Companies (YIC) are the two recent funding incentives European countries have implemented. 
(Ernst & Young, pg.65) FP7 brings together European research initiatives to gain economic 
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growth, competitiveness and employment. (cordis.europa.eu/fp7/understand_en.html) Its primary 
goal is to build a knowledge based European economy by funding food, agriculture, and 
biotechnology research. YIC is a status a company can achieve which grants them exemption for 
certain taxes and social contributions. The goal of granting these exemptions is to promote R&D 
and decrease the amount of time it takes to get new products out to the public. Also, to encourage 
the growth of pipelines European governments are currently pushing for tax breaks in cross-
border trading similar to that of NAFTA between America, Mexico, and Canada. Many see “the 
lack of corporate tax harmonization across the EU is often viewed as being detrimental to the 
competitiveness of European business.” (Ernst & Young, pgs.65-66). 
 
2.3.3.4 – America 
Unlike China, India, and Europe, U.S. governmental policies have been problematic for 
its biomedical industry. Many of the governmental policies that give the Asia – Pacific and 
European regions their competitive advantages are almost opposite to that of America‟s.  These 
policies have damage almost all areas of America‟s competitive advantages with specifics to 
education, financing, patent issuance, and indirectly internal demand. 
As mentioned in the section about the global biotechnology industry, one of the largest 
problems the global industry is facing is the “fourth hurdle”  (Ernst & Young). America has been 
especially affected by this need for price regulations on pharmaceutical drugs. America‟s age 
demographic is getting older and older due to advancements in the medical field which has 
dramatically increased the life expectancy of people (Ernst & Young). Health care is becoming 
increasingly expensive with these aging demographics which have created debates on the 
regulation of drug prices. If governments impose strict pricing limits then the companies will not 
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be able to produce the drug. If the companies set too high of a price, the decreasing middle class 
and lower class will not be able to afford the drugs which will give the same result (Ernst & 
Young). Congress has worked towards alleviating this dilemma with acts such as the Medicare 
Modernization Act‟s “non-interference” clause which prohibits the government from directly 
negotiating with manufacturers on prices. The Secretary of the Department of Health and Human 
Services would however have this right (Ernst & Young). 
It is becoming increasingly harder for biomedical companies to obtain patents and 
develop new products due to the laws and regulations set in place by the U.S. government. A lot 
of the problems stem from the strict policies of the FDA and the increasing concerns of ideas for 
products and research being stolen. Some other problems involve trade and financing. NIH 
funding, which has been one of the largest sources of federal funding, has gone down in the 
biomedical industry. Also, America‟s strict trade and foreign entry policies has caused venture 
capital to decrease and has put us at a disadvantage to Europe‟s strong pipeline and networking 
system, which has provided it with related and supporting industries and increased product 
development. 
 
2.3.4 - Research Institutes & Incubators 
2.3.4.1 – China 
The Chinese government has been creating biomedical parks and a high-tech zone since 
the 1980‟s, providing incubating facilities for biomedical companies. These high-tech zones 
provide several benefits and have helped prosper the push for a more R&D oriented industry. 
Firms in these high-tech zones benefit from tax incentives, “a new governance model”, and an 
increase in business clusters. The governance model focuses on “a smaller government with 
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more services” and helps firms “reduce their transaction costs and more efficiently facilitate their 
activities.” The business clusters formed within these zones help provide a stronger networking 
system, which allows companies to benefit from each other‟s research and successful attributes, 
as well as increasing prosperity within the industry as a whole. (Liu & Lundin, pg. 76) 
Approximately ninety percent of China‟s high-tech firms and incubators are now located 
in these high-tech zones and by the year 2005 over 490 incubators had been created across the 
country. Although the majority of these firms and incubators are information technology 
oriented, the biomedical firms have a large presence and benefit greatly from these other 
companies. In the past these incubators were funded and managed mostly by governmental 
agencies. Recently, the government has been encouraging joint ventures, large corporations, and 
private investors to invest in these incubators and as a result, over half of them are currently 
funded, established, and owned by non-governmental investors. (Liu & Lundin, pg. 76) 
These actions have greatly helped the government‟s goal in shifting to a more R&D 
oriented biomedical industry. The incubators provide the facilities, funding, support, and 
opportunities biomedical firms need to do R&D activities. The non-governmental and foreign 
investments in these incubators have and will continue to produce a growth within the industry 
that because of limited resources; the Chinese government is not capable of. (Liu & Lundin, pg. 
76) 
 
2.3.5.2 – America 
 America has the largest and strongest biomedical clusters in the world and is greatly 
supported by its incubators and research institutes (MBC). Its biomedical incubators are used as 
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a model for the rest of the world and are considered to be the best and most efficient. They have 
allowed startup companies to enter the industry with great success, which consequently has 
increased the number of companies, employees, and economic impact of the U.S. biomedical 
industry. On top of that, America has some of the most prestigious colleges and universities in 
the world which have provided a knowledgeable labor force to the industry as well as additional 
R&D and biomedical facilities. 
 
2.3.5 - Education 
2.3.5.1 - China & India 
Both the Chinese and Indian governments have been supporting their academic facilities 
for many of the same reasons, their main goal being to promote the sciences so that there will be 
a more knowledgeable and experience workforce to enter the biomedical industry. The 
educational trends are so similar between the two countries that this section will solely focus on 
China. The Chinese government has contributed a lot of funding and support to its country‟s 
universities and hospitals. Both the government and Chinese citizens realize that the biomedical 
industry is the most prominent and prosperous in the country. Two important occurrences stem 
from this realization, the first being socially related and the second governmentally. The Chinese 
people realize that being educated in the biomedical field is the fastest and best way to achieve 
success financially and career wise. For this reason, there is a large population of biomedical 
students and graduates ready to enter and contribute to the industry. (Liu & Lundin, pgs.53-55) 
There has also been a large influx of foreign-educated Chinese who have returned to work in 
biomedical industry in China. (Ernst & Young, pg. 77) The government wants to encourage and 
support this phenomenon in order to help increase the level of research and development in the 
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industry. They do this by giving funding directly to the universities as well as encourage and 
fund the development of incubators. (Liu & Lundin, pg.55) 
There are two main reasons why universities are such an integral part of the biomedical 
industries. The first reason is that they contribute to the networking system previously discussed. 
The second reason is that it produces a large educated workforce for the industry. This is very 
appealing to foreign investors. Not only does China have a large workforce, it has a large 
educated workforce that can be hired for cheaper wages and salaries. Having this type of 
workforce not only helps the biomedical industry as a whole, it helps the government make the 
transition from a predominantly manufacturing industry to a knowledge based R&D one. 
 
2.3.5.2 – America 
 According to a surveys done by Ernst & Young as well as PricewaterhouseCoopers, 
many biomedical companies feel that education for science in the K-12 grades has been severely 
lacking. According to Ernst & Young, America is 20
th
 in the world for high school science 
proficiency. Finland and Japan tied for number one and Korea came in at number two. In 
general, America‟s high school science proficiency is severely lacking compared to the European 
and Asia – Pacific regions. 
 
2.3.6 - Outsourcing and Globalization 
2.3.6.1 – China 
Even though outsourcing and globalization has many disadvantages and has negatively 
affected the economies of some countries, it has greatly benefited China and its biomedical 
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industry. Foreign investment has become an important necessity for the industry and is one of the 
main reasons for its rapid growth. It mainly began with China‟s induction into the World Trade 
Organization and was further promoted by the government and environmental conditions such as 
an educated workforce.  
As mentioned before, the industry was originally based on the intense manufacturing of 
biomedical products. There were little to no patents granted to organizations so imitation and 
generic drugs became a popular product to produce. Since manufacturing became such a big part 
of the industry, the government feared that by giving patents industry growth would falter. When 
the government decided to join the WTO and increase R&D in the industry patent laws were 
changed and became more frequent. This allowed foreign investors to comfortably establish 
themselves in China without any fear of losing the products they create to other competition. 
(Liu & Lundin, pgs. 4-5) 
Two other reasons foreign investors became interested in China are the large, cheap, and 
educated workforce it provides (previously discussed in the education section) and its openness 
to controversial scientific research. Many countries in the world do not approve of research done 
on stem cells and gene therapy and therefore make it illegal to do so. China does not have any 
restrictions in these areas of research. Many large biomedical companies will establish 
themselves in China solely for this reason. (Liu and Lundin, pg.23) 
 
2.3.6.2 – India 
According to Naleish A. Bhatt, author of 2007 article Dynamics of India‟s Life Sciences 
Outsourcing Industry, the World Trade Organization‟s implementation of the General 
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Agreement on Tariffs and Trade/Agreement on Trade-Related Aspects of Intellectual Property 
(GATT/TRIPS) in India, opened up its biotechnology and pharmaceutical industries to the 
effects of outsourcing. (Bhatt, pg.65) He believes that this event changed these industries in three 
different ways. An increased level of comfort among global pharmaceutical and biotechnology 
companies encouraged doing work in India as well as with Indian companies. Several global 
investors sought to invest in the different fields of their biomedical industry and Indian corporate 
executives shared this eagerness to cooperate with global investors. After the implementation of 
this agreement India‟s biomedical industry became more diverse and grew to become one of the 
leading biomedical markets. (Bhatt, pg.65) 
The Indian biomedical industry‟s increased exposure to outsourcing and its resulting 
metamorphosis and growth greatly resembles what occurred in China around the same time. 
Both countries biomedical industries were originally based on the heavy manufacturing of 
generic drugs and cheap medical devices. The lack of property rights in India prospered this 
manufacturing trend and at the same time discouraged foreign companies to invest in their 
industry. When the WTO implemented the GAFT/TRIPS agreement, both of the country‟s 
biomedical industries became more R&D and service oriented. Their market shares in the 
industry greatly increased as well due to increased outsourcing and foreign investment. India is 
the second most sought after country by global investors and China is currently the first. (Bhatt, 
pg. 67) 
Bhatt believes that one of the main reasons for the increased level of outsourcing is a 
higher comfort level of global investors and that several of factors are responsible for this. An 
important contributing factor to the increased level of comfort is “India‟s liberal and attractive 
investment policies, coupled with highly liquid financial markets.”  Instead of foreign companies 
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simply investing in an Indian corporation, they invest directly into specific projects. Some other 
key factors that Bhatt listed in his article are the presence of scientists with experience in global 
firms, proof that Indian companies can create value in a cost effective manner, and large 
opportunities in healthcare created by the Indian population. Once again, this is comparable to 
what happened in China. In general, an educated workforce, cheaper operational costs and 
opportunities for growth as a result of their current populations encouraged increased foreign 
investment. (Bhatt, pg. 67) 
 
2.3.6.3 – Europe 
Several of companies in Europe have established pipelines not just among themselves, 
but with the U.S. and Asia as well. Keeping up with the trends of globalization, European 
companies have made several mergers and acquisitions as well as alliances with predominantly 
countries within Europe and with America. In 2006 mergers and acquisitions between European 
countries increased by 59 percent. It increased 36 percent with America and 5 percent with Asia. 
Many of the companies preferred to make deals in Europe to acquire American companies and 
create mergers and alliances between pharmaceutical and biotech companies. Although Europe‟s 
level of cross national deals is low compared to that of America‟s and Asia‟s, the European 
biotechnology industry has been able to sufficiently keep up with the increasingly necessary 
trends of globalization. (Ernst & Young, pgs.57-60) 
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2.4 – Regional Industry 
2.4.1 – Colleges of Worcester Consortium (COWC) 
 The Colleges of Worcester Consortium (COWC) exists to develop and manage 
collaborative services that enhance the educational missions and improve the operational 
effectiveness of its member institutions. The Consortium is a not-for-profit organization which 
was founded in 1968 by the presidents of the colleges and universities. These college leaders 
recognized it was desirable to jointly address common issues of importance to their institutions, 
to higher education in the region, and to their communities. COWC currently has thirteen 
governing-member colleges and thirteen associate members located in Central Massachusetts of 
which membership is voluntary. The thirteen colleges and universities which comprise the 
Colleges of Worcester Consortium, Inc. include nine Worcester-based institutions and four 
institutions in the greater Worcester area. A list of all colleges within COWC is in Table A. This 
unique partnership offers students a number of benefits, including cross-registration among the 
colleges, dual-degree programs, cooperating library privileges and a variety of collaborative 
career services. Its mission is to work cooperatively to further the missions of the member 
institutions individually and to advance higher education regionally. The Consortium has three 
major areas of focus: to provide organizational effectiveness and shared services among its 
college and university members; to provide access to higher education opportunities for low-
income students and adults; and to cultivate local and regional economic development and civic 
engagement opportunities. (COWC 2007) 
 Besides supporting the education, COWC also has a strong impact on Greater Worcester 
and the State of Massachusetts. The Consortium helped its member institutions communicate 
their economic, intellectual, educational, and cultural impact on Greater Worcester and the 
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Commonwealth of Massachusetts with special emphasis on serving the local region and its 
people. Also, The Consortium enhanced the economic benefits to members through increased 
emphasis on programs and services that provide cost savings and efficiencies. 
 Recently, most colleges within the COWC have built their own life science facilities (e.g. 
Worcester Polytechnic Institute just opened its biotechnology centers called Gateway Park; and 
the College of Holy Cross is in the midst of constructing a $60 million Integrated Science 
Complex). Therefore, MBI wanted to look at the trend of COWC and its impact on the 
biomedical incubator industry within the Central Massachusetts. 
Figure 1: Colleges of the Worcester Consortium 
 Colleges Within COWC 
1 Anna Maria College 
2 Assumption College 
3 Atlantic Union College 
4 Becker College 
5 Clark University 
6 College of the Holy Cross 
7 Massachusetts College of Pharmacy and Health Sciences 
8 Nichols College 
9 Quinsigamond Community College 
10 Tufts Cummings School of Veterinary Medicine 
11 University of Massachusetts Medical School 
12 Worcester State College 
13 Worcester Polytechnic Institute 
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2.5 – Benchmarking 
Benchmarking will be the most important method for evaluating the current standing of 
the biomedical industry on a regional, national, and global scale. Benchmarking is the process of 
improving performance by continuously identifying, understanding, and adapting outstanding 
practices and processes found inside and outside the organization or from organizations 
anywhere in the world (American Productivity & Quality Center). The objective of 
benchmarking is to understand and evaluate the current position of a business or organization in 
relation to best practice and to identify areas and means of performance improvement. In 
addition, benchmarking helps organizations identify standards of performance in other 
organizations and to import them successfully to their own. It allows organizations to discover 
where they stand in relation to others. By identifying, understanding, and comparing the best 
practices and processes of other organizations with its own, an organization can target problem 
areas and develop solutions to achieve best levels of performance.  
Benchmarking is often done by companies and organizations who want to improve their 
effectiveness and expand their businesses. Benchmarking efforts typically collect information on 
responsibilities, program design, operating facilities, technical know-how, brand images, levels 
of integration, managerial talent, and cost of financial performance. Companies and 
organizations benchmark for many reasons: they want to determine where they spend their time 
and how much value they add, or they are curious about how they stack up against others. 
Through the knowledge gained by benchmarking, organizations and companies redefine their 
roles, add more value, reduce costs, and improve performances. (Blinn 1998) 
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There are three methods of benchmarking that could be used in determining the economic 
impact of the Central Massachusetts biomedical industry: competitive, generic, and functional 
benchmarking.  
1. Competitive benchmarking involves analyzing outside organizations that are 
known to be the best in their industry. Competitive benchmarking provides 
opportunities of learning from those who are at the leading edge. Typically this is 
done by reviewing trade publications and competitor literature, and by hiring 
individuals who are familiar with competitor processes. In competitive 
benchmarking, a consultant or a third party rather than the organization itself 
collects and analyzes the data because of its proprietary nature. (Hurwicz 1998) 
2. Generic benchmarking investigates activities that are or can be used in most 
businesses. This type of benchmarking makes the broadest use of data collection. 
One difficulty is in understanding how processes translate across industries. Yet 
generic benchmarking can often drastically alter an organization‟s ideas about its 
performance capability and result in the reengineering of business processes. 
(Evans 1999) 
3. Functional benchmarking involves the analysis of a particular function which may 
be common within an industry. This is typical for automated processes that utilize 
commercially available software. A team of potential software users will visit a 
business that has agreed to serve as a show case for the software. This type of 
benchmarking is an opportunity for breakthrough improvements by analyzing 
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high-performance processes across a variety of industries and organizations. 
(Camp 1995) 
Benchmarking is a tough process that needs a lot of commitment to succeed. Its models 
are used to determine how well a business unit, division, organization or corporation is 
performing compared with other similar organizations (Christopher E. Bogan, 2003). However, 
not all benchmarking projects are accurate. More than once benchmarking projects end with the 
“they are different from us” syndrome or competitive sensitivity prevents the free flow of 
information that is necessary (Value Base Management.Net).  
Typically, there are a lot of steps that involve within benchmarking process. In order to 
generate the three benchmarking methods that we mentioned above, the following steps need to 
be done. First, a project team must identify the scope definition of the benchmarking project, 
which we already did. The next step would be determining which benchmark partners to choose, 
as well as determining specific benchmark values by collecting and analyzing information from 
surveys, interviews, industry information, direct contacts, business or trade publications, 
technical journals, and other sources of information. Then we will start making data collection 
and analysis of the discrepancies. The fourth and most important step is that a project team will 
present the results and discuss implications or improvement areas, and come up with the 
improvement plans or new procedures. (George 1992) 
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2.6 - Forecasting  
The process by which organizations ponder and prepare for the future that involves 
predicting the future outcome of various business decisions is known as forecasting. Forecasting 
provides organizations important information on the future business as a whole, the future of an 
existing or proposed product, and the future of the industry in which the business operates. In 
order to forecast, a project team uses existing data, facts, and rely on technical and fundamental 
statistics to predict the direction of the economy and the industry. Accurate forecasts are used by 
organizations to assist them in making business decisions and give them the opportunity to grow 
their businesses effectively in the related industry.  
Forecasting is important to our project because one of the major objectives of this project 
is to make a five-year prediction as to where the biomedical incubator industry is going and on 
where Worcester region position is in the future. There are several different methods that can be 
used to create a forecast. The method a forecaster chooses depends upon the experience of the 
forecaster, the amount of information available to the forecaster, the level of difficulty that the 
forecast situation presents, and the degree of accuracy or confidence needed in the forecast. The 
most basic method of forecasting which could be used for Massachusetts Biomedical Initiatives 
is the “Qualitative Forecasting Methods”. Qualitative Forecasting Methods are based on 
educated opinions of appropriate persons. They have three different sub-methods that could be 
used to forecast the industry: Market research and expert judgment.  
Market research is the process of systematic gathering, recording and analyzing of data 
about customers, competitors and the market. Market research can help the company create a 
business plan, launch a new product or service, fine tune existing products and services, and 
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expand into new markets. It can be used to determine which portion of the population will 
purchase the product or service, based on variables like age, gender, location and income level. 
Market characteristics of target market can be found out. (MacNamara n.d.) With market 
research, companies like MBI can learn more about current and potential customers, as well as 
the trend of biomedical incubator industry.  
Expert judgment is an approach for soliciting informed opinions from individuals with 
particular expertise. This approach is used to obtain a rapid assessment of the state of knowledge 
about a particular aspect of climate change. It is frequently used in a panel format, aggregating 
opinions to cover a broad range of issues regarding a topic. Expert judgment is frequently used to 
produce position papers on issues requiring policy responses and is integral to most other 
decision-making tools. (Smith 1990) 
Another method of forecasting which also may be used is the “Causal/Econometric 
Method”. Causal forecasting methods are based on a known or perceived relationship between 
the factor to be forecasted and other external or internal factors. This forecasting method is based 
on the process of analyzing and developing the statistical models through research, existing data, 
and economic principle in order to make prediction for the economic in the future. Causal 
forecasting is concentrated on four different models: regression, economics, input-output, and 
simulation model. Regression model is based on mathematical equation which relates a 
dependent variable to one or more independent variables that are believed to influence the 
dependent variable. Econometric models are the system of interdependent regression equations 
that describe some sector of economic activity. An input-output model is used to describe the 
flows from one sector of the economy to another, and so predicts the inputs required to produce 
outputs in another sector.  The advantage behind the Causal/Econometric Method is that it 
 47 
provides a more accurate forecasting, but in contrast, it is often so complicated and is not simple 
to generate. (Sparling 2006) 
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3.0 – Methodology 
3.1 - Determining the Economic Impact of Central Massachusetts 
 In order to determine the impact of the Central Massachusetts biomedical industry, we 
first had to define what Central Massachusetts consists of. Using maps and county data, we 
found the cities or towns that make up Central Massachusetts and the Worcester country. This is 
shown in Appendix A. 
 The number of life science companies in Central Massachusetts was collected using 
archival research on national databases, companies‟ websites, and available business journals. 
One important source that the project team used was the information published by the 
Massachusetts Biotechnology Council (MBC). Based on the information on October 2007, MBC 
has a total of 566 companies as members. 352 of them are biotechnology companies and 47 
companies are nonprofit research institution (including MBI). Another important source was the 
Massachusetts Medical Device Industry Council (MassMedic). However, both MBC and 
MassMedic do not show all of the life science companies in Central Massachusetts.  
The team also contacted the town clerk office in Worcester to get a list of all the 
companies that have been started up in the past five years. Every company is required to register 
with the government when they establish themselves which mean that the town clerk has a 
comprehensive list of the startup biomedical companies. However, this does not provide 
information on how many employees they have, how much revenue they generate and other 
financial data. This information is hard to collect due to company protectionism, so we did not 
go into an extensive search for it. 
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To determine the economic impact of the Central Massachusetts biomedical companies, 
we used the same method as the 2004 report.  It followed the same strategy as determining the 
impact of WPI and extended it to a broader level. To do this we had to separate the data by 
companies with less than 500 employees and more than 500 employees in order to gain a more 
accurate average of the number of employees in Central Massachusetts. To find a more accurate 
number of the employees, we used the equation provided in the 2004 report. We then multiplied 
it by the average expenditure per full time employee to determine the economic impact. 
 
3.1.1 – Boston – Worcester Corridor and Other Regions 
 
 On top of the Central Massachusetts biomedical industry, we analyzed the Boston – 
Worcester corridor, the North Shore, and another area we labeled as Northern Massachusetts. 
The Boston – Worcester corridor includes the Boston area which is Boston, Cambridge, and 
Greater Boston. Greater Boston is the surrounding area of Boston that is within the route 95 line. 
The North Shore is the area above Greater Boston and Northern Massachusetts lies to the west of 
that. These areas and their corresponding list of cities can be found in Appendix B. 
 To find the economic impact of these areas we followed the same methodology as the 
Central Massachusetts. We made a list of companies and the number of employees they have, 
found the average FTE costs, and then multiplied that by the total number of employees to get 
the economic impact. We then used these numbers to make regional comparisons and determine 
the percentage these areas take up of the Massachusetts biomedical industry. Comparisons were 
made using the total number of companies and employees, average FTE costs, and economic 
impact.  
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These comparisons were not made to show that one area is doing better than the other or 
to suggest that these regions are in competition with one another. One of the goals of this project 
is to promote interaction between these regions so that the entire Massachusetts biomedical 
industry can grow. These comparisons were done for a couple different reasons. The first one 
was to see if the numbers we obtained are relatively close to what has been seen in the past and 
what are currently expected. If they do not match then it can be assumed that these figures are 
not accurate. The other reason was to simply get a breakdown of where the concentrations of 
regional biomedical industries fall within the Massachusetts biomedical industry.  
 
3.2 – Benchmarking the Massachusetts Biomedical Industry and Beyond 
 An extension to this study was benchmarking the biomedical industry on a statewide, 
national, and global level. Essentially, the same methods were used to benchmark on all levels 
and mainly consisted of market analysis data. To benchmark Massachusetts, we first found a set 
of metrics used in previous benchmarking studies and then compared Massachusetts to the top 
biomedical industries in the United States. Because these studies are done infrequently, we found 
the latest data that could be applied to all of the states even if some of them had more up to date 
analysis. The differing data must be consistent with dates and unless it is being compared to its 
past self, data cannot be compared at different points in time and at different levels. For this 
reason, we could not incorporate current Massachusetts biomedical industry data into the 
benchmark. Many analyst studies of state biomedical industries provided all information of the 
metrics so extensive data mining was not necessary. 
 The same method was used to benchmark the United States biomedical industry and the 
rest of the world. The only difference is that instead of analyzing the top biomedical states, we 
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analyzed the top biomedical countries. We used general global reports as well as country 
analysis to do this. The Ernst & Young report was our only global source we had due to a lack of 
studies done on this scale. Data mining techniques and the OECD was used to analyze particular 
countries. 
 
3.3 - Impact of the COWC 
Recently, many colleges within the Colleges of Worcester Consortium (COWC), built 
their own life science facilities (e.g. Worcester Polytechnic Institute (WPI) just opened a 
biotechnology center called Gateway Park), and have contributed greatly to the Massachusetts 
biomedical industry. The team contacted Mark Bilotta who is the Chief Executive Officer (CEO) 
of COWC.  We asked Mr. Bilotta some specific questions pertaining to the size of the life 
science center at each college, how much was spent to build these facilities, and the specialty at 
each facility. In addition, we asked Mr. Bilotta to provide a list of contact information of the 
project managers or individuals who were responsible for development of the life science 
centers. We asked these managers more in depth questions regarding specific information of the 
science center at their school, as well as their opinion on the status of the biomedical industry in 
the Central Massachusetts.  
In order to determine the impact of the COWC we used these resources to find out how 
many startup companies have come out of these colleges and universities. Using the same 
method we used in determining the impact of the Central Massachusetts biomedical industry, we 
determined the impact these schools had on the industry. We also found how many biomedical 
graduates the schools were graduating per year and how many patents were issued through the 
companies and their studies. 
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3.4 - Forecasting 
Forecasting is the important method for making prediction on the biomedical incubator 
industry. In order to forecast, our project team had used a few methods including interviews with 
a few groups of experts within the biomedical incubator industry. For instance, two of the people 
we interviewed were from the Massachusetts Biotechnology Council (MBC) and Massachusetts 
Medical Device Industry Council (MassMedic). These interviews were mainly used to gain 
qualitative data. Specific questions that focused on the trends of the industry were asked. Also, 
the team requested for useful data including industry reports which provided both quantitative 
and qualitative data needed to forecast the industry. Market research methods were also used to 
collect data. We looked at available electronic resources such as databases, electronic reports, 
MBC and MassMedic websites, etc. 
Benchmarking was a key tool in forecasting the biomedical industry‟s status in the next 
five years. By having current and past data, we were able to determine growth rates in several 
fields. We looked at key growth rates such as market capitalization, patent distribution, revenues, 
net loss, employment, etc.  To determine these growth rates, we used past and present industry 
averages and then extended it to five years using a linear equation as well as compounding. The 
basic equation was X*(1+A)^R where X is the 2007 data, A is the average growth rate per year, 
and R is the number of years being forecasted (in most cases five years). Charts and graphs were 
an essential tool in forecasting the biomedical industry.  
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3.5 - Market Research 
 In order to benchmark the biomedical industry the team collected market research with 
specifics to corporate data and industry data analysis on a regional, statewide, national, and 
global level. Some important factors that were analyzed are total sales, total employment and 
employment rates, exports, land occupation, etc. The numbers for these factors were obtained 
from current and past market reports given by corporations, industry analysis, MBI, and past 
MQP reports. Some specific sources we used were government sites such as the census, 
biomedical councils, interviews, library databases, and more. When the team collected a 
sufficient amount of research, we analyzed the data and used benchmarking methods to 
determine the state of the industry. 
 
3.5.1 - Analysis 
 The method the team used to analyze the market research is the SWOT analysis. 
Typically SWOT analysis is used as a strategic planning tool for a project and a business 
venture. In this case, the team used it as a planning tool and a means of an evaluation for the 
biomedical industry. The SWOT analysis involves determining the strengths, weaknesses, 
opportunities, and threats of internal and external conditions. Based on this, the team determined 
the strengths and weaknesses of the industry based on the quantitative research. These data were 
provided by the market analysis, corporate reports, and by interviews, articles, government 
involvement and regulations, population trends, etc. 
Determining the opportunities and threats of the industry was part of the forecasting 
section of the project. The team determined where we believe the biomedical industry will be 
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five years from now by analyzing the opportunities and threats discovered through mainly 
qualitative research. That is not to say that quantitative research was not used to make these 
predictions. 
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4.0 – Analysis 
 This chapter contains two main sections. The first section shows the economic impact of 
the Central Massachusetts biomedical industry. It explains how we found the number of 
companies and employees as well as how we found the economic impact by using an average 
FTE cost. The second section benchmarks the Massachusetts biomedical industry with other 
states in the United States. It also benchmarks the biomedical industry of the United States with 
other prominent countries. We feel that these numbers are fairly close to accurate based on our 
research and professional studies. We found 1,133 companies in the Massachusetts biomedical 
industry and the PricewaterhouseCoopers estimated the number to be around 1,150 companies. 
Based on this our numbers and calculations should be fairly accurate. 
 
4.1 – Economic Impact of Central Massachusetts 
  To find the economic impact of the Central Massachusetts biomedical industry, we had 
to do three steps. The first step was to compile a list of all the companies located in Central 
Massachusetts which was done with resources such as MBC, MassMedic, and MacRae‟s Blue 
Book. We used this list to make a database of all the pertinent company information which 
included whether or not it was a startup, the number of employees, and contact information. If 
we could find the number of employees in our data sources then we contacted the companies 
either by phone or email. We also contacted the companies to get their average FTE costs.  
Because we could not get the number of employees for every company, an average was 
done and added to the total number of employees calculated in the database. The total number of 
employees we found in Central Massachusetts was 12,742 which came to an average of 82 
 56 
employees per company. There were 45 companies without employee information. ((82*45) + 
12742) came to a total of 16,441 employees in Central Massachusetts.  
Every company in the Central Massachusetts database was contacted to obtain their 
average FTE costs. Forty-one of the 162 (25%) companies gave out this information and the FTE 
costs averaged out to be about $150,000. In order to be consistent with the 2004 report we took 
out all the companies that had an FTE cost of $175,000 or higher. The average went down to 
approximately $133,000 per full time employee. The number of employees times the average 
FTE cost gives us the economic impact of the Central Massachusetts biomedical industry, which 
turned out to be around $2,200,000,000. 
 
4.1.1 – Benchmark of the Central Mass Biomedical Industry 
 Benchmarking the economic impact of the Central Massachusetts industry with past 
information allows us to see how the industry has fared within the last three years and helps us 
forecast its level of economic impact five years from now. In 2004 the economic impact was 
approximately $925,000,000 and the average FTE cost was $128,000.  In 2007 it was about 
$2,200,000,000 and $133,000 respectively. This resulted in a growth of 136 percent for the 
economic impact and about four percent for the FTE Cost. The table and charts show the below 
mentioned changes. 
  2004 2007 Difference % Change 
Average FTE Costs $128,000 $132,580 $4,580 3.58% 
Economic Impact $925,000,000 $2,179,764,221 $1,254,764,221 135.65% 
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Figure 2: FTE cost in Central Mass 
 
Figure 3: Economic Impact in Central Mass 
 
Not only has the economic impact of the Central Massachusetts biomedical industry gone 
up, the number of employees and companies have gone up as well. The number of employees 
has gone up 117 percent from 7,576 employees in 2004 to 16,441 in 2007. The number of 
companies in Central Massachusetts went up 46 percent from 111 in 2004 to 162 in 2007. Also, 
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we found a total number of approximately 30 startup companies. Startup companies are defined 
as any company that has been established within the past five years including the time it has 
spent in an incubator. We cannot make a comparison to 2004 because the startup companies they 
included in their study are also included in ours. Below are the graphs to show the change in 
employees and companies in Central Massachusetts. 
 
Figure 4: Central Mass Employees 
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Figure 5: Central Mass Companies 
 
 
4.2 – Economic Impact of the other Massachusetts Regions 
 As well as finding the economic impact of Central Massachusetts, we found the 
economic impacts of other regions within Massachusetts. We found the economic impacts of the 
Boston – Worcester corridor, the Boston area, Greater Boston, and the North Shore. This was 
done for a few reasons. One of the main goals of this project was to determine the economic 
impact of the Boston – Worcester corridor. In order to do this we needed to research the Boston 
and Greater Boston areas which are part of the corridor. We also studied these areas so that we 
can compare them to each other and determine what percentage of the industry they make up. 
 
4.2.1 – Boston & Greater Boston 
 We define the Boston area as Boston and Cambridge. Greater Boston is the major cities 
surrounding the Boston area that are within route 95. The Boston and Cambridge area has the 
highest concentration of biomedical companies and employees. It is the epicenter and birth area 
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of the Massachusetts biomedical industry. The Boston area has about 184 companies and 16,478 
employees. It has an average FTE cost of about $158,000 which results in an economic impact of 
approximately $2.6 billion. The Greater Boston area has about 254 companies and 16,000 
employees. We did not find the average FTE cost and economic impact due to time constraints 
but that did not greatly affect the numbers for the Boston – Worcester corridor. 
 
4.2.2 - Boston - Worcester Corridor 
 As defined before, the Boston – Worcester corridor is Boston, Cambridge, Greater 
Boston, Worcester County, and everything within route 9, 2, 190 and the Mass Pike. We used the 
same methodology as before to find the number of companies and employees, the average FTE 
costs, and the economic impact. Within this area there are about 690 companies and 46,759 
employees. The average FTE cost was $154,918, which results in an $8.8 billion economic 
impact. 
 
4.2.3 – North Shore 
 The North Shore is a rapidly growing area for the biomedical industry. It has the benefit 
of being located close to Boston without the heavy amounts of traffic and congestion. This is one 
of the many attractive features that bring in biomedical companies into the North Shore. It has 
about 82 companies and 5,400 employees. The average FTE cost is $149,500 which results in an 
economic impact of $805 million. 
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4.3 – Regional Comparisons 
 As mentioned before, we are not trying to show that the different biomedical regions in 
Massachusetts are competing with each other. It is our intent to convey the necessity of these 
regions to work with each other in order to create a stronger Massachusetts biomedical industry. 
The reason we make these comparisons is to simply show the makeup of the industry and where 
the strong concentrations of biomedical companies and employees lie. 
 The first two charts compare the Boston – Worcester Corridor to the rest of 
Massachusetts. It contributes 62 percent of the companies and 56 percent of the employees in 
Massachusetts. According to expert opinion, these numbers are actually surprising. The numbers 
are lower than expected and the percentage of companies and employees in the “other” category 
are higher than anticipated. Although there is no past information to support this claim, the 
numbers and expert opinion suggests that companies are starting to spread out more in 
Massachusetts. Whether or not they cannot be determined until future information is acquired. 
Figure 6: Regional Comparisons (Companies) 
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Figure 7: Regional Comparisons (Employees) 
 
 The next two charts compare the largest biomedical regions in Massachusetts. When 
looking at these numbers, the sizes of the different regions need to be considered. The company 
comparison looks relatively normal based on qualitative data from case studies as well as expert 
opinions. The Boston area and Greater Boston have the highest concentrations of companies. 
Boston is the birthplace of the Massachusetts biomedical industry and has always had the highest 
percentage of companies. Worcester County accounted for 24 percent of the companies and the 
North Shore accounted for 12 percent. Based on the size and age of these regions, these are not 
surprising numbers. 
 The employee comparison is a bit more deceiving. Worcester County accounts for 30 
percent of employees, which is larger than Greater Boston and very close to Boston. Boston and 
Greater Boston have historically had the largest concentration of employees and has been 
unrivaled by other regions. The reason why the Worcester County percentage is so high is 
because it covers a much larger area than any of the other regions. If only Worcester and Boston 
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where compared then the numbers would look more accurate. The North Shore has the lowest 
percentage mainly due to the fact that it is a relatively new area for the biomedical industry. 
However, it is a rapidly expanding area and is expected to grow substantially in the near future. 
Figure 8: Major Areas Company Comparison 
 
Figure 9: Major Areas Employee Comparison 
 
 The last chart compares the economic impact of the Central Massachusetts, the Boston 
area, and the North Shore. Many factors relating to the economic impact equation need to be 
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considered when comparing these numbers. As a reminder, the equation is the average FTE cost 
times the total number of employees in that particular region. The average FTE costs of these 
three regions were relatively the same. This is not surprising considering that we took the 
average costs of companies with similar functions, products, and operations. The number of 
employees between Worcester County and Boston area were relatively the same. Worcester 
accounted for 30 percent and Boston was 31 percent. Keeping in mind the size of the two 
different areas, it is not surprising that the number of employees were relatively the same. 
Therefore it only makes sense that the economic impacts were about the same. The North Shore 
has substantially less employees and therefore only accounted for 14 percent of the economic 
impact of the three regions. 
Figure 10: Economic Impact Comparison 
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4.4 – Benchmark of the Massachusetts Biomedical Industry 
 The Massachusetts biomedical industry has been one of leading industries in the United 
States for years and continues to grow rapidly. In the Israel Biotechnology Strategy Project, 
many of the graphs show the Israeli biomedical industry compared to Massachusetts and even 
shows a chart with MIT and Harvard University on it. This implies that Massachusetts is a world 
recognized leader in the biomedical industry. 
It may seem that Massachusetts has the leading biomedical industry in the United States, 
however, it remains second to California. 
 
4.4.1 - Massachusetts Biomedical Industry Past and Present 
 The first step in benchmarking Massachusetts is showing the level of progress it has 
made in the past years. For employment, the industry employed a total of 71,600 people in 2001, 
74,100 people in 2005, and 102,586 employees in 2007. Between 2001 and 2005, the number of 
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employees increased by 3.5 percent and between 2005 and 2007 it increased by 38.4 percent. 
The graphs below illustrate these changes.   
Figure 11: Massachusetts Employees 
 
The number of biomedical companies in 2004 was 1,347 (Schafer 2004) and about 1,150 in 2007 
(PricewaterhouseCoopers). There was a 14.6 percent decrease between these dates. It is not 
uncommon for the number of biomedical companies to go down in number because mergers and 
acquisitions of companies are a frequent occurrence in this industry. Although there is no 
evidence to show this is what actually happened, it is a high possibility. 
 
 
 
 
2005 2007
74,100
102,586
Mass. Employees
 67 
Figure 12: Massachusetts Companies 
 
4.4.2 - State Comparisons 
 As mentioned before, Massachusetts has one of the leading biomedical industries in the 
United States. California remains number one in many different aspects, but Massachusetts 
continues to be considered one of the best states for the industry. The following section compares 
Massachusetts with some of the top leading states in six different areas. These areas are 
commonly used metrics in benchmarking the biomedical industry and where provided by the 
SuperCluster report done by PricewaterhouseCoopers.  
 
4.4.2.1 - Funding 
 One of the largest sources of funding to the biomedical industry is the National Institutes 
of Health (NIH). The NIH provides many states with funding towards their biomedical or life 
science industries and usually allocates its money based upon three different qualifications. The 
NIH “looks for grant proposals of high scientific caliber that are relevant to public health needs 
that are within the NIH Institute and Center‟s priorities.” It “encourages investigator-related 
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research across the spectrum of its mission.” Also, the projects the individual or institution is 
conducting must be unique in the sense that they have never been done before. Based on these 
qualifications here are the rankings of the states that received the most funding from the NIH. 
(U.S. Department of Health & Human Services 2008) 
Figure 13: NIH Funding & Grantee 
NIH Funding Per Capita 2005 
 (dollars) 
Mass 353 
Maryland 316 
Connecticut 131 
Washington 129 
N. Carolina 124 
Rhode Island 123 
Pennsylvania 117 
Vermont 108 
New York 105 
PricewaterhouseCooperss: SuperCluster 
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NIH Grantee States 2005 
 (millions) 
California 3,301 
Mass 2,273 
New York 2,021 
Maryland 1,764 
Penn. 1,452 
Texas 1,150 
N. Carolina 1,078 
Washington 813 
Illinois 734 
PricewaterhouseCoopers: SuperCluster 
Per capita, Massachusetts came in first for NIH funding in 2005 but in terms of total funding to 
the state in came in second, behind California. In 2007, NIH funding went down in both 
California and Massachusetts. California went down $138 million from 2005, which is a 4.18 
percent decrease, and Massachusetts went down $37 million, which is a 1.62 percent decrease 
(National Institutes of Health (NIH) 2007). The difference between Massachusetts‟s NIH 
funding and California‟s state funding in 2007 was $927 million and in 2005 it was 
approximately $1 billion, which suggests that the gap is getting smaller and Massachusetts is 
slowly gaining more dominance over California in the biomedical industry 
(PricewaterhouseCoopers). 
 Another common economic indicator and comparison tool for most industries (as 
opposed to NIH funding which is usually associated with the biomedical industry) is venture 
capital. Venture capital directly correlates with the growth of a nation, industry, or business, in 
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the sense that a lot of it goes towards the development of new companies and research. An 
increase in new companies results in an increase in employment, new products, and economic 
contributions to the company‟s home state or country. Below is the state ranking for venture 
capital investment in the biomedical industry. 
Figure 14: Venture Capital 
Venture Capital 2006 (Approximate) 
 (millions) 
California $3,300 
MA $1000 
PA $500 
New Jersey $400 
Washington $400 
Maryland $300 
Colorado $250 
Minnesota $250 
N. Carolina $200 
PricewaterhouseCoopers: SuperCluster 
4.4.2.2 – Employment  
 Having a competent and qualified workforce is one of the competitive advantages Porter 
describes in his essay. The competitive advantages mentioned in the section on Porter, could be 
applied to different levels including state and corporation, which is why employment is an 
important indicator of how well an industry is doing. Although we do have more updated 
information on employment for Massachusetts and California, we have information from 2005 
for several of the other leading biomedical industries. Below are the rankings for biomedical 
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employment by state in 2001 and 2005. It is labeled as Life Science Employment, but, in this 
case, the terms are synonymous.  
Figure 15: Life Sciences Employment 
Life Sciences Employment 
     
 2001 2005 Difference % Change 
U.S. 1,739,200 1,842,400 103,200 5.9% 
California 247,400 260,700 10,900 5.4% 
New York 120,500 122,800 2,300 2.0% 
New Jersey 113,400 108,300 -5,100 -4.5% 
Mass 71,600 74,100 3,300 3.5% 
N. Carolina 50,500 59,500 9,000 17.7% 
PricewaterhouseCoopers: SuperCluster 
In 2007, Massachusetts employed approximately 100,000 people within the biomedical industry. 
This is still lower than the biomedical employment in New Jersey, New York, and California in 
2005. Assuming that California and New York‟s biomedical employment continued to grow over 
the years, it is a good possibility that Massachusetts is still below them in the rankings. However, 
based on the same assumption that these states are continuing their growth trends, it is also 
possible the Massachusetts grew to be larger than New Jersey. 
 
4.4.2.3 Education 
 As mentioned before, having an educated and qualified workforce can give a company, 
state, or even country, a competitive advantage over its competitors. That being said, obviously 
education is an important part in creating this caliber of a workforce. Massachusetts has always 
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been an epicenter of education in the world and holds some of the most prestigious colleges. 
Education is one of Massachusetts‟ strongest assets and it shows even within the biomedical 
industry. According to the PricewaterhouseCoopers “SuperCluster” report on the life science 
industry and the National Science Foundation, Massachusetts came in first for the number of 
degrees given out in the biology, chemistry, and chemical engineering fields. Here are the 
rankings of states for these degrees. 
Figure 16: Life Sciences PhDs 
Life Sciences PhDs Granted per 100,000 People 
    
 Biology Chemistry Chem. Eng. 
MA 6.51 2.05 0.90 
Maryland 3.88 0.45 0.30 
New York 3.13 0.72 0.28 
N. Carolina 3.10 0.92 0.16 
PA 2.22 0.89 0.48 
California 2.05 0.81 0.28 
PricewaterhouseCoopers: SuperCluster 
4.4.2.4 - Biotechnology 
 Although biotechnology is not the same as biomedical, it is in fact a subsection of it and 
comprises the majority of the industry. Below is a comparison chart done by Ernst & Young on 
the biotechnology industries of different regions in the United States. It provides comparisons of 
many of the metrics used to benchmark any industry and gives a good picture of how well the 
New England area is doing in the U.S. biotechnology market. This does not effectively show 
Massachusetts place within the biotechnology market which was the original goal but it does at 
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least give an idea of how well it is doing considering that it has the strongest 
biomedical/biotechnology industry in the region. (Note: We took out two sections to reduce 
space and because they were not pertinent to this project) 
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Figure 17: Financial Highlights of U.S. Biotech Company 
Selected 2006 U.S. biotechnology public company financial highlights  
[by geographic area, (US $m), percent change over 2005] 
Region 
# of Public 
Companies 
Market Capitalization 
31.12.06 
Revenue R&D Total assets 
SF Bay Area 
69 $145,553 $17,688 $7,485 $31,678 
0% 10% 15% 65% -7% 
New England 
60 62,936 10,384 3,919 26,216 
3% 5% 16% 31% 4% 
San Diego 
38 20,916 3,252 1,432 8,589 
3% 6% 18% 32% 8% 
New Jersey 
28 28,556 1,747 802 3,196 
-3% 71% 23% 10% -13% 
Mid-Atlantic 
23 17,111 2,061 1,270 7,210 
15% 13% 8% 11% 10% 
Southeast 
19 5,301 544 271 1,423 
0% -25% -64% -34% -53% 
New York 
17 8,893 1,373 685 3,533 
13% 25% 97% 6% 4% 
Mid-West 
8 1,161 121 90 342 
-11% -28% 16% -10% 7% 
Pacific NW 
15 4,928 196 521 1,245 
0% 22% 17% 19% -9% 
LA/Orange County 
11 81,585 14,692 4,898 32,946 
0% -18% 14% 94% 9% 
North Carolina 
9 2,017 326 191 735 
0% -2% -11% -14% 2% 
(Ernst & Young) 
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We have highlighted areas of importance to more easily compare New England to other regions. 
There are a couple of things to notice when looking at this chart. First, although it comes in third 
for almost all of the categories, regions in California are the only ones that outrank it. This 
suggests that Massachusetts comes second only to California in many of these areas. Second, 
New England has the same growth rate for the number of public companies as all the regions in 
California, which suggests that Massachusetts is growing at a similar rate. 
 
4.4.3 - Global Biotechnology Industry 
 Using the economic metrics provided by the Ernst & Young report, it is apparent that the 
global biotechnology industry is continuing to grow. It is not apparent as to how fast the industry 
has been growing or how much it has grown over the years from this data, but it does show that 
it has been both growing and growing fast. Global biotechnology revenues went up 14 percent 
between 2005 and 2006. R & D expenditures went up 33 percent mainly due to strong emerging 
industries such as the ones in China and India. The number of employees went up 10 poercent 
and the number of companies went up .3 percent. The chart below provided by Ernst & Young 
displays these figures. 
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Figure 18: Growth in Global Biotech 
Growth in global biotechnology, 2005 - 2006 
Public company data: 2006 2005 Change 
Revenues (US $m) 73,478 64,213 14% 
R&D expense (US $m) 27,782 20,934 33% 
Net loss (US $m) 5,446 4,039 35% 
Number of employees 190,500 173,110 10% 
Number of companies: 
Public companies 710 673 5% 
Public and private companies 4,275 4,263 0.3% 
(Ernst & Young) 
 In chapter two, we analyzed the global biotechnology industry using Porter‟s Competitive 
Advantage. Due to a lack of sufficient information, we were not able to organize this section in 
the same manner. It does, however, provide key metrics that are commonly used in 
benchmarking the biotechnology industry. Once again, Ernst & Young who is a trusted source 
for financial and economic data provided these metrics and their respective charts. 
 
4.4.3.1 - Financial & Economic Metrics 
Below is a similar chart as above comparing some of the financial metrics between the 
U.S., Europe, and the Asia-Pacific region. 
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Figure 19: Global Biotech at a Glance 
Global biotechnology at a glance in 2006 
Public company data Global U.S. Europe Asia-Pacific 
Revenues (US $m) 73,478 55,458 11,489 3,289 
R&D expense (US $m) 27,782 22,865 3,631 401 
Net loss (US $m) 5,446 3,466 1,125 331 
Number of employees 190,500 130,600 39,740 12,970 
Number of companies 
Public companies 710 336 156 136 
Public and private companies 4,275 1,452 1,621 737 
(Ernst & Young) 
The U.S. continues to be the leader in the global biotechnology industry in every way except 
one. Its revenues, R & D expenses, and number of employees are significantly higher than the 
other two regions. Whether or not its growth in these areas is higher or even significant is 
unknown due to the lack of past data. It is possible, however improbable, that the Asia-Pacific 
region‟s growth rates are higher due to its expanding prominence within the global 
biotechnology industry. 
 Financing is also a largely used metric in benchmarking any industry. A country‟s 
openness to others based on governmental policies, is one of Porter‟s competitive advantages. He 
believes that it is important for a country to have favorable economic policies towards outsiders 
in order to gain the types of finances shown below. The following chart compares the U.S. and 
Europe in three areas of financing. 
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Figure 20: U.S. and Europe Financial 
The year in Financing: U.S. and Europe 2005 and 2006, (US $m) 
  2006 2005 Change 
Type U.S. Europe U.S. Europe U.S. Europe 
Initial Public Offering (IPO) 944 907 626 691 51% 31% 
Follow-on and other offerings 16,067 3,069 10,740 1,577 50% 95% 
Venture Financing 3,302 1,907 3,328 1,738 -1% 10% 
Total $20,313 $5,883 $14,694 $4,006 38% 47% 
(Ernst & Young) 
Although the U.S. has a higher percentage of IPO‟s between 2005 and 2006, it significantly lacks 
in the other two areas of financing compared to Europe. Its total financing also had a smaller 
percentage change compared to Europe. Once again, this is probably due to the increased 
governmental policies that are making it more difficult for companies to develop and produce 
more products.  
 
4.4.3.2 – Educational Metrics and Patents 
 As mentioned in chapter two, education is a highly important metric and is essentially 
one of the comparative advantages Porter describes. It is especially important in the 
biotechnology industry where almost every job requires an extensive education within its fields. 
Patents are also a widely used metric in the biotechnology industry and are indicator of how 
many products are successfully being developed by companies within the industry. Below is a 
chart showing the rankings of countries based on these metrics. Scientific paper citations are 
usually associated with education as it is in the chart below. 
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Figure 21: Scientific Competitiveness 
Scientific competitiveness: Selected indicators 
Country 
Scientific paper 
citations 
Share of global 
biotechnology 
patents 
High school 
science 
proficiency 
Growth in 
biotechnology 
patent 
applications 
Value Rank Value Rank Rank Value Rank 
U.S. 37,822 1 43.3% 1 20 1.5% 20 
UK 7,565 2 5.3% 4 - 2.8% 19 
Germany 7,497 3 9.6% 3 14 10.1% 6 
Japan 6,298 4 14.1% 2 1 8.2% 9 
France 5,172 5 3.6% 5 12 6.3% 14 
Canada 4,194 6 2.7% 6 8 5.2% 16 
Italy 3,363 7 1.0% 15 22 8.1% 10 
Netherlands 2,665 8 1.7% 9 5 5.8% 15 
Australia 2,273 9 2.1% 7 5 3.9% 17 
Switzerland 2,168 10 1.4% 12 10 9.0% 8 
China 1,481 13 1.7% 9 - 49.3% 1 
India 789 below 20 0.8% 16 - 30.4% 2 
(Ernst & Young) 
The U.S. is at number one for both scientific paper citations and its share of global biotechnology 
patents. What is interesting to notice is that it is ranked 20
th
 for high school science proficiency 
and its growth in biotechnology patent applications. According to the PricewaterhouseCoopers 
report on the Massachusetts “SuperCluster”, one of the industries growing concerns is the 
proficiency students have in science at the elementary to high school levels. This seems to be the 
case for most of America judging by its ranking. Its ranking for growth in biotechnology 
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applications is no surprise considering that it has become increasingly harder to get patents due 
to government policies. 
 Europe is following a similar path as America in terms of its rankings. Europe‟s countries 
are highly ranked in the first two fields but fall short with education proficiency and patent 
growth. China and India on the other hand have experienced the complete opposite of Europe 
and America. Their share in global biotechnology patents and scientific paper citations is very 
low. Their growth in biotechnology patent applications is however ranked one and two. China 
was ranked at number one and India at number two. This is not surprising considering their 
governments have made great strides to reduce restrictions on patents and to ease the process of 
obtaining them.  
 
4.4.3.3 – Global Alliances 
 The sharing of physical resources, products, and information is an essential part to the 
growth of the global biomedical industry. Not only does it benefit the industry, it benefits the 
consumers in the sense that alliances allow for more breakthroughs and products that will help 
people‟s daily lives. Alliances bring in more venture capital, information, resources such as 
educated labor, revenues, etc. The danger of alliances though is the decrease in competition, 
which Porter describes as an essential component to an industries growth. It also has the ability 
to hurt the development of startup companies in the sense that information becomes too widely 
available and susceptible to being stolen. Below is a chart showing Europe‟s share of alliances 
with the biotechnology industries in America and Asia. 
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Figure 22: Alliances by Regions 
Share of alliances by region, 2001 - 2006 
Region 2001 2002 2003 2004 2005 2006 
Europe-Europe 37% 34% 47% 41% 50% 49% 
Europe-U.S./North America 56% 55% 43% 49% 40% 40% 
Europe-Asia 7% 11% 10% 10% 10% 11% 
  (Ernst & Young) 
As you can see, Europe maintains alliances primarily with itself and mostly with America after 
that. What is interesting to notice is the decrease in the share of alliances with America over the 
years. This could be due to Americas increasing patent restrictions and product approval policies. 
Asia has remained relatively the same over the years but it is more than likely to increase as it 
becomes a stronger entity within the global biotechnology industry. 
 
4.5 - Forecasting 
 Using a simple linear equation and compounding, we determined the 2010 and 2012 data 
for the number of companies, employees, and economic impact of the Central Massachusetts 
biomedical industry. The original goal was to determine the 2012 data, but we included 2010 to 
show the linear progression from 2004 more effectively. We applied the same methodology to 
the Massachusetts biomedical industry, however, we could not forecast its economic impact 
because of the lack of data. No numerical forecasting was done for the United States and global 
biomedical industry for the same reason. The forecasted numbers represent a simple linear 
extrapolation, but it is treated in this report as the upper bound of growth these areas are expected 
to grow if we assume the growth rate remains the same. In reality, it is not likely for these 
industries to reach these levels, therefore we use qualitative data to develop a more realistic 
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growth forecast. The following sections only include brief descriptions of the charts provided. It 
is only meant to provide the numerical part of our forecasting process. Further analyses of the 
numbers are done in the following chapter. 
 
 
4.5.1 – Central Massachusetts 
Based on our linear equation, the number of companies in Central Massachusetts will grow 46 
percent in 2010 and 88 percent in 2012. 
 
Figure 23: Forecasted Central Mass Companies 
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The number of employees in Central Massachusetts will grow 117 percent in 2010 (2.2 times the 
amount of 2007) and 264 percent in 2012. 
Figure 24: Forecasted Central Mass Employees 
 
In 2010 the economic impact will grow to $5.1 billion (a 136% increase) which is more than 
double 2007. In 2012 it will grow 317 percent to about $9.1 billion. 
Figure 25: Forecasted Central Mass Economic Impact 
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4.5.2 – Massachusetts 
Figure 26: Forecasted Mass Companies 
 
The number of companies dropped between 2004 and 2007 causing a negative growth rate. It is 
not uncommon for the number of companies to go down in this industry due to large number of 
mergers and acquisitions.  It would, however, be doubtful for the number of companies to 
continue to decline based on the overall industry growth. Even though these numbers suggest the 
number of biomedical companies in Massachusetts will go down, we believe that it will do just 
the opposite. We analyze this further in the next chapter. 
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Figure 27: Forecasted Mass Employees 
 
In 2010 the number of people employed in the Massachusetts biomedical industry will go up to 
about $174,000 in 2010 which is a 69.5 percent increase. In 2012 it will grow 141 percent to 
approximately $250,000. 
 
4.6 – SWOT Analysis 
 We did a SWOT analysis for all the different levels of the project. That includes the 
Central Massachusetts, Massachusetts, and the global biomedical industry (U.S., Europe, and 
Asia Pacific). We used this information to further expand on our forecasting. The growth we 
found through linear projection is unrealistic and is intended only to show what would happen if 
growth remained the same.  For a variety of reasons, however, that is not likely to occur.  
Therefore, we use the information in the SWOT analysis to determine how accurate the numbers 
are and how much the selected metrics of these industries will actually grow. 
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4.6.1 – Central Massachusetts 
 Strengths 
o Large and prestigious academic community 
o Knowledgeable workforce 
o Large amount of companies and employees 
o Has biomedical incubators such as MBI 
o Away from Boston traffic 
o Comparatively lower living costs 
 Weaknesses 
o Distance from the Boston area 
 Limited access to its resources 
o Insufficient K-12 life science education 
 Opportunities 
o Planned stem cell research center at UMASS Medical in Worcester 
o Governor Patrick‟s life science initiative 
 Threats 
o Decreases in NIH funding 
o Strict patent application process 
o Negative governmental drug pricing policies 
o Struggling U.S. economy 
o  
4.6.2 – Massachusetts 
 Strengths 
o One of the largest biomedical clusters in the world 
 Provides related and supporting industries 
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o High levels of financing 
 Number one for NIH funding per capita (2nd by state) 
 Government, corporate, & private 
 Number 2 in the U.S. for receiving venture capital 
o 2
nd
 in the U.S. for R&D expenses 
o Large amount of Employees & Companies 
 4th in the U.S. for life science employment 
 Weaknesses 
o High levels of traffic 
o Insufficient k-12 life science education 
o Decreased patent issuance 
o Expensive labor force 
 Opportunities 
o Governor Patrick‟s 1 billion dollar life science initiative 
 Threats 
o Decreasing NIH funding 
o Struggling U.S. economy 
 
4.6.3 – Global 
The following information is once again organized using Porter‟s Competitive Advantages 
4.6.3.1 – America 
 Strengths 
o Large amounts of capital 
o High internal demand 
 Large elderly population 
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o Strong hold on the technology industry 
 One of the largest contributors to the growth of the biomedical industry 
o Largest amount of financing and venture capital 
o Large knowledgeable workforce 
o Has the largest and most prominent biotechnology clusters 
o Large amount of tax incentives 
 Weaknesses 
o Strict patent application process 
 Decrease in patent applications 
o Strict trade laws 
 Low level of trade incentives 
o Decreased federal funding 
o Insufficient K-12 life science education 
o Problematic drug pricing policies 
o Decreasing overseas alliances 
 Opportunities 
o Combating its own weaknesses 
o Creating alliances with Europe and especially China 
 Threats 
o China‟s rapidly expanding biomedical industry 
o Europe‟s strong relations with other countries 
 
4.6.3.2 – Europe 
 Strengths 
o Strong inter-country relations through 
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 Trade incentives 
 Pipelines & networking 
 Common currency 
 Lenient foreign entry policies 
o Large amounts of funding & venture capital 
 Second only to America 
o 17 large biomedical clusters between 
 U.K. 
 Germany 
 France 
o Most amount of alliances with foreign countries 
 Weaknesses 
o None found 
 Opportunities 
o Increased alliances with America and China 
 Threats 
o America and the Asia – Pacific region 
4.6.3.3 – Asia Pacific 
 Strengths 
o Strong hold on underdeveloped niches 
 Stem cell, gene therapy, & traditional Chinese medicine 
o Improved patent laws 
o Large government funding for education and business development 
o Incubators & high tech zones 
o Improved foreign entry policies 
o Improved safety and environmental policies 
 Weaknesses 
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o Communist country 
 Makes it harder for foreign companies to establish businesses there which 
can reduce venture capital 
 Low trade incentives 
o Comparatively smaller labor interests in the biomedical industry 
o Patent laws are still not as effective as other countries 
o Still a young developing industry 
 Opportunities 
o Improve patent, trade, and foreign entry policies and take advantage of its rapid 
growth 
 Create alliances with America and Europe 
 Threats 
o Europe & America 
 
4.7 – Forecasting Justification  
As we discussed at the beginning of the previous section, the predicted numbers using a 
linear compounding equation are not a reliable or accurate portrayal of how well the biomedical 
industry will actually do. The numbers represent what we believe is the maximum growth the 
industry will see for that particular metric. Also, this assumes that the industry‟s growth rate will 
continually increase over that period of time. If those numbers are in fact accurate, then we can 
assume that the industry faces few problems and is constantly improving itself. It is likely that 
this will not occur, which is why we need to incorporate qualitative data and get a better picture 
of how much the industry will actually grow. Our key tools in doing this were the SWOT 
analysis, and expert opinions which we received through contacts and interviews, current events, 
and case studies.  
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All of the experts we contacted were agreed that the Central Massachusetts biomedical 
industry will grow in terms of companies and employees during the next five years. On the other 
hand, we looked at different resources, such as EBSCO, Scenario Thinking, and the U.S. 
Department of Labor Employment and Training Administration. These resources predicted that 
the economic impact for the United States biomedical industry will experience an increase of 
about 13-14 percent and employment of about 12-13 percent between 2006 and 2012.  
From the SWOT analysis and case studies we learned that the Central Massachusetts 
biomedical industry is currently facing problems such as reduced NIH funding, decreased 
issuance of patents, increased governmental regulation of prices, and more (we will discuss more 
briefly in the next chapter). All of these lead us to believe that the growth rate of the Central 
Massachusetts will be higher than the rate for the United States in both economic impact and 
employment, but will be lower than the defined growth rate using the linear equation. Therefore 
we came up with the new growth rate by taking average of the United States‟ growth rates with 
our defined growth rates in Central Massachusetts. We applied this equation for all three 
categories: economic impact, employment, and number of companies.  
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4.7.1 – Central Massachusetts  
Based on above equation, the number of companies in Central Massachusetts will grow 67 
percent (10.7% annually) between 2007 and 2012.  
Figure 28: Central Mass Companies (Adjustment) 
 
 
Figure 29: Central Mass Employees (Adjustment) 
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Between 2007 and 2012, the number of employees in Central Massachusetts will grow 159 
percent (21% annually). 
 
 
Figure 30: Central Mass Economic Impact (Adjustment) 
 
 
The economic impact in Central Massachusetts will grow 182 percent (23% annually) to about 
$6.1 billion in 2012.  
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4.7.2 – Massachusetts 
 
Figure 31: Mass Employees (Adjustment) 
 
 
Using the equation, the number of employees will increase by about 105 percent (15.5% 
a year) by 2012. That is a total of 210,466 employees. The U.S. employment growth rate was 
around 13 percent so we are fairly confident that this is a reasonable estimate. We cannot 
effectively predict the number of companies because the original growth rate was negative 
causing the numbers to go down. However, based on our qualitative information we believe that 
the number of companies in Massachusetts will increase beyond the 2005 number, which was 
1,347. 
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5.0 – Conclusions and Recommendations 
 This chapter serves two purposes. The first purpose is to make conclusions on our 
forecasting. We already determined the numerical portion of the forecasting. The next step is to 
use the qualitative information we have gathered to make better forecasts of the different 
industries. The second purpose of this section is to make recommendations on how the industries 
can improve. 
 
5.1 – Forecasting Conclusions 
5.1.1 – Central Massachusetts 
 All of the experts we contacted were agreed that the Central Massachusetts biomedical 
industry will see substantial growth in the coming years. When contacting these experts we 
mainly asked them how they feel the overall industry is doing and what they believe will happen 
to it in the future. We specifically talked about if the number of companies and employees will 
increase over the years. We did not ask about what they think the economic impact of the Central 
Massachusetts will do because we did not have the information at the time and it was a relatively 
unfamiliar subject to them. The experts all agreed that Central Massachusetts biomedical 
industry will see substantial growth in terms of companies and employees. Using this 
information and the quantitative data we forecasted, we determined that the industry will see 
relatively high growth rates in employment and number of companies. Based on the equation we 
used to find the economic impact, we figured out that if the number of employees in the region 
increases, the economic impact will increase with it. That means we should see a substantial 
growth rate for the economic impact of Central Massachusetts as well.  
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 We also gained confidence that the industry will grow because of Governor Patrick‟s life 
science initiative. Not only will Central Massachusetts receive a good portion of the funding, it 
will be receiving a state of the art stem cell research center. This will be located in Worcester at 
UMASS Medical School. Stem cell research is a hot topic in America and a lot of states will not 
allow it due to moral issues presented by the public and some government representatives. Many 
companies on the other hand are very eager to do research on this subject. Having a stem cell 
research center in Worcester will probably bring a lot of biomedical companies and labor into the 
area. On the other hand, growth rates from other studies suggest that our numbers will not be as 
high. Even though these studies were done on the United States biomedical industry, they give us 
more of an idea of what the actual growth rates will be. Economic impact for the United States 
biomedical industry has a growth rate of about 13-14 percent and employment has around 12-13 
percent. 
 From the SWOT analysis and case studies we did learn that the Central Massachusetts 
biomedical industry is currently facing some problems. Patents are becoming harder to get which 
inhibits a lot of R&D and the production of new products. It has been said that life science 
education has been less than satisfactory in grades K-12. NIH funding is going down 
everywhere. Price regulations put in place by the government have made it difficult for 
pharmaceuticals to produce drugs at a profit and the overall economy is declining. All of these 
problems are not specific to Central Massachusetts. They are general problems the United States 
biomedical industry is facing and every state and region is feeling its affects. It is very possible 
that Central Massachusetts has only incurred a small amount of these problems which leads us to 
believe that the growth rates will be relatively high. 
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 Based on all of this information, we believe that the growth shown in the forecasting 
graphs is relatively accurate. The numbers, expert opinion, and current events lead us to believe 
this. This is not to say that an industry can go without its problems. The problems discussed 
above suggest that the industry will not see the growth suggested by the numbers in the graphs. 
Although possibly minor for this region, they are factors that would inhibit the growth of the 
industry.  Instead of the number of companies growing 88 percent between 2007 and 2012, 
which is what the graph shows, it is more likely that it will grow around 67 percent (10.7% 
annually). That is a total of 270 companies in 2012. We arrived at this number by taking average 
of the United States‟ growth rates with our defined growth rates in Central Massachusetts. 
Because the problems associated with the Central Massachusetts biomedical industry are 
relatively minor and the numbers and expert opinion suggest substantial growth, the actual 
company, employee, and economic impact growth should be in the high range.  We applied this 
same method for employees and the economic impact. Employment will grow around 159 
percent (21% annually) which results in a total of 42,644 employees by 2012.  Also, the 
economic impact will grow approximately 182 percent (23% annually). That is a total of $6.1 
billion by 2012.  
Even though these growth rates are significantly higher than those of the United States, 
they are not surprising considering Massachusetts has had higher growth rates in this sector than 
the United States for several years now. The annual growth rates in Central Massachusetts for 
economic impact and employment are almost two times larger than the United States. As we will 
discuss in the next section, Massachusetts‟ growth rate for biomedical employment is almost 
twice as large as that of the United States. Based on this we believe that our adjusted forecast is 
relatively accurate. 
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5.1.2 – Massachusetts 
 A lot of the information we received on Central Massachusetts was the same as what we 
got for Massachusetts. Expert opinions and case studies suggested that the Massachusetts 
biomedical industry will see a lot of growth within the next five years. It will also gain more 
benefit from the governor‟s life science plan that the Central Massachusetts industry will receive.  
On the other hand, the problems listed for Central Massachusetts are the same for Massachusetts 
as a whole. The difference is that the Massachusetts biomedical industry is affected more heavily 
by their impacts. On top of that, other unique problems exist for Massachusetts such as the traffic 
problems that exist in Boston. 
 Based on this data we believe that the Massachusetts biomedical industry will in fact see 
a lot of growth in the next five years but not to the extent Central Massachusetts will. Using the 
same methodology we used to predict the new growths for Central Massachusetts, we found a 
more accurate prediction of the Massachusetts biomedical industry. Because the problems are 
more severe for Massachusetts as a whole, it is more likely that the actual growth will be below 
these adjusted numbers.  
 
5.1.3 – America 
 Since there was not enough numerical data to make mathematical predictions like the 
ones for Central Massachusetts and Massachusetts, all of the predictions made for the United 
States biomedical industry where made using qualitative information. Currently, the United 
States biomedical industry is the largest and strongest in the world. It has the largest amount of 
capital, a high level of internal demand, a strong hold on the technology industry, a large 
knowledgeable workforce, the largest and most prominent biotechnology clusters, and it has the 
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highest amount of financing and venture capital. These are the competitive advantages the 
United States has which make it the number one biomedical industry. They help steer the flow of 
trade in the American biomedical industry which is why it is the most profitable. 
 Despite America‟s numerous competitive advantages, it is facing some serious problems 
and if the government does not do something about it, it is quite possible that America will lose 
its ranking as the number one biomedical industry. China‟s biomedical industry is growing faster 
than any other countries. It has made several reformations and initiatives to grow its biomedical 
industry and it has seen a lot of success because of it. They also have numerous competitive 
advantages which are threatening to America‟s industry. They have the largest labor force in the 
world and with government programs, funding, and incentives; they are becoming very well 
educated in the life sciences. They have made a dramatic shift from manufacturing to R&D. 
Also, the government is making stronger patent laws and policies which used to be a major issue 
in China. If the America government does not start changing many of its policies that negatively 
affect the biomedical industry, there is a strong possibility that China will exceed us and become 
the number one biomedical industry in the world. 
 There is also a good chance that Europe will one day beat out America if we do not start 
changing our policies. Europe has liberal foreign entry and trade laws and has several tax 
incentives to encourage trade. Because of these policies, Europe has developed strong 
networking abilities and has more alliances between countries than both American and the Asia-
Pacific region. If China does in fact obtain the number one biomedical industry in the world, it is 
more than likely that Europe will become a close second because of their trading policies, 
networking abilities, and alliances. 
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5.2 – Recommendations 
 A lot of the recommendations made in this section apply to all three of the industries 
discussed in the previous section. The same recommendations are applicable to Central 
Massachusetts, Massachusetts, and the United States because they share a lot of the same 
problems. The common problems are decreased NIH funding, stricter patent application policies, 
drug-pricing policies, and insufficient levels of life science education in grades K-12. A lot of 
these problems need to be addressed by the federal government but some of them may be able to 
be dealt with through the Massachusetts state government. 
 The federal government should increase funding for education, business development, 
and R&D through their NIH program as well as others. It needs to find a balance between putting 
price caps on pharmaceutical and medical device products and letting the companies set their 
own prices. If the companies cannot produce a profit then the public cannot benefit from their 
new products. On the other hand, if the products are too expensive then the public would not be 
able to benefit from them anyway. This is why a balance needs to be found between regulating 
prices and letting companies set their own prices. The federal government should also change 
their patent and drug development policies so that companies can make a faster transition from 
R&D to production. Also both the federal and state government should create stronger life 
science educational programs for grades K-12. Massachusetts specifically should find ways to 
solve the transportation issues. Public transportation programs and better commuter rail systems 
are a couple of options to help reduce traffic.   
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Appendix A: Central Massachusetts 
Map 1: Actual Central Massachusetts 
 
This map defines the region of Massachusetts presented by the Department of Business and 
Technology. 
Table 1: List of Towns and Cities in the Actual Central Massachusetts 
Ashburnham 
Ashby 
Ashland 
Athol 
Auburn 
Ayer 
Barre 
Berlin 
Blackstone 
Bolton 
Boxborough 
Bolyston 
Brookfield 
Framingham 
Gardner 
Grafton 
Groton 
Hardwick 
Harvard 
Holden 
Holliston 
Hopedale 
Hopkinton 
Hubbardston 
Hudson 
Lancaster 
Milford 
Millbury 
Millville 
Natick 
New Braintree 
Northborough 
Northbridge 
North Brookfield 
Oakham 
Oxford 
Paxton 
Pepperell 
Petersham 
Southborough 
Southbridge 
Spencer 
Sterling 
Stow 
Sturbridge 
Sutton 
Templeton 
Townsend 
Upton 
Uxbridge 
Warren 
Webster 
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Charlton 
Clinton 
Douglas 
Dudley 
Dunstable 
East Brookfield 
Fitchburg 
Leicester 
Leominster 
Littleton 
Lunenburg 
Marlborough 
Medway 
Mendon 
Phillipston 
Princeton 
Royalston 
Rutland 
Shirley 
Shrewsbury 
West Brookfield 
Westborough 
West Boylston 
Westminster 
Winchendon 
Worcester 
This is a list of all the cities and towns that report to the Central Massachusetts Chamber of 
Commerce (Department of Business and Technology, 2003). 
 
Map 2: Worcester County 
 
As shown in the Massachusetts GIS map. 
www.state.ma.us/mgis/ix_cnty.gif 
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Table 2: List of Towns and Cities in Worcester County 
Ashburnham 
Athol 
Auburn 
Barre 
Berlin 
Blackstone 
Bolton 
Bolyston 
Brookfield 
Charlton 
Clinton 
Douglas 
Dudley 
East Brookfield 
Fitchburg 
Gardner 
Grafton 
Hardwick 
Harvard 
Holden 
Hopedale 
Hubbardston 
Lancaster 
Leicester 
Leominster 
Lunenburg 
Mendon 
Milford 
Millbury 
Millville 
New Braintree 
Northborough 
Northbridge 
North Brookfield 
Oakham 
Oxford 
Paxton 
Petersham 
Phillipston 
Princeton 
Royalston 
Rutland 
Shrewsbury 
Southborough 
Southbridge 
Spencer 
Sterling 
Sturbridge 
Sutton 
Templeton 
Upton 
Uxbridge 
Warren 
Webster 
West Brookfield 
Westborough 
West Boylston 
Westminster 
Winchendon 
Worcester 
As listed in the Massachusetts election county separations. 
http://www.state.ma.us/sec/ele/elecct/cctidx.htm#worc    
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Appendix B: North Shore area 
 
Table 1: List of Towns and Cities in North Shore 
Amesbury   Lynn    Revere  
Beverly   Lynnfield   Rockport  
Boxford   Malden   Rowley  
Chelsea   Manchester   Salem  
Danvers   Marblehead   Salisbury  
Everett    Melrose   Saugus 
Georgetown   Merrimac   Swampscott 
Gloucester   Middleton   Topsfield 
Groveland   Nahant    Wakefield 
Hamilton   Newbury   Wenham 
Haverhill   Newburyport   West Newbury 
Ipswich   Peabody   Winthrop 
 
As listed in: www.boston.com/jobs/northshore/ 
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Appendix C: Biomedical Companies in Worcester County 
Company Name Address 
Town/City, State, Zip 
Code 
Phone 
Number 
ABBOTT Bioresearch Center, Inc. 100 Research Drive Worcester, MA 01606 508-849-2500 
Abco Welding & Industrial 
Supply, Inc. 31 Sword St Auburn, MA 01501 508-791-9293 
ACMI Corporation 136 Turnpike Road Southborough, MA 01772 508-804-2600 
Advanced Cell Technology Inc  One Innovation Drive Worcester, MA 01605 508-756-1212 
Aearo Co. 90 Mechanic Street Southbridge, MA 01550 508-764-5500 
Albright Technologies Inc 25 Litchfield St Leominster, MA 01453 978-466-5870 
Alpha Analytical Labs 8 Walkup Drive Westborough, MA 01581 508-898-9220 
Alpha-Beta Technology Inc 
(ABTI) One Innovation Drive Worcester, MA 01605 508-798-6900 
Analox Instruments Usa Inc 104 Sunset Ln Lunenburg, MA 01462 978-582-9368 
Antigen Express Inc  100 Barber Avenue Worcester, MA 01606 508-852-8783 
AO SOLA 14 Mechanic Street Southbridge, MA, 01550 508-764-5000 
Araios Inc. One Innovation Drive Worcester, MA 01605 617-413-3020 
Arrhythmia Research Technology 
Inc. 25 Sawyer Passway Fitchburg, MA 01420 978-345-5000 
Athena Diagnostics, Inc  377 Plantation Street Worcester, MA 01605 508-756-2886 
Ats Laboratories Inc       
Attogen Inc. 100 Barber Ave Worcester, MA 01606   
Auralgesic Company, Inc. 16 Johnson Way Rutland, MA 01543 508-886-6749 
Avecia Biotechnology, Inc. 125 Fortune Ave Milford, MA 01757 508-532-2500 
Averica Discovery Service Inc. 
One Innovation Drive, 
Biotech III Worcester, MA 01605 508-757-4600 
Averion International Corp  225 Turnpike Road Southborough, MA 01772 508-597-6000 
Bioactives LLC 1 Dix Street Worcester, MA 01609 617-489-0424 
BioDynamics, Inc. 29 Prospect Street 
West Boylston, MA 
01583 508-835-6258 
Biohybrid Technologies 910 Boston Turnpike Road Shrewsbury, MA 01545 508-842-4460 
Biomeasure, Incorporated 27 Maple Street Milford, MA 01757 508-478-0144 
Biomedical Polymers Inc 42 Linus Allian Ave Gardner, MA 01440 978-632-2555 
Biomedical Research Models, Inc  10 New Bond Street Worcester, MA 01606 508-852-0606 
BioPal, Inc. 80 Webster Street Worcester, MA 01603 508-770-1190 
Biopartners Inc 10 Andy Rd Worcester, MA 01602 508-755-4645 
BioReliance Biotech Inc. 381 Plantation Street Worcester, MA 01605 508-791-8000 
Biosource, Inc. 
1200 Millbury Street Suite 
7F Worcester, MA 01607 508-363-2367 
BioValve Technologies Inc. One Innovation Drive Worcester, MA 01606 508-421-9500 
BioVest International, Inc.  377 Plantation St, Biotech 4 Worcester, MA 01605 508-793-0001 
Blue Sky Biotech, Inc.  60 Prescott Street Worcester, MA 01605 508-831-1295 
Boston Medical Products, Inc. 117 Flanders Road Westborough, MA 01581 508-898-9300 
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Brendan Bioscience, LLC  3A Business Way Hopedale, MA 01747 508-473-8899 
Brochu Bio-Lab Services 400 Thompson Road  Webster, MA 01570 508-943-9750 
BURLE Electro-Optics, Inc. 
 PO Box 1159, Sturbridge 
Bus. Park Sturbridge, MA 01566 508-347-4000 
Cellthera Inc. 431 High Street Southbridge, MA 01550 508-765-0276 
Central Coating Co, Inc.  165 Shrewsbury St 
West Boylston, MA 
01583 508-835-6225 
CereMedix, Inc. One Innovation Drive Worcester, MA 01605 508-459-5924 
Charles River 57 Union St Worcester, MA 01608 508-890-0100 
Coley Pharmaceutical Group, Inc. 93 Worcester St. Wellesley, MA 02481 781-431-9000 
Consistent Cardiogram Corp 25 Winthrop Street Worcester, MA 01604   
Cool Laser Optics 57 E Main Street Westborough, MA 01581 508-870-0066 
Crescent Innovations Inc       
Cryogenic Institute of New 
England 90 Ellsworth St Worcester, MA 01610 508-459-7447 
Cyberkinetics Neurotechnology 100 Foxborough Blvd. Foxborough, MA 02035 508-549-9981 
Databased Inc       
Dosco Sheet Metal & mfg 6 Grafton St Millbury, MA 01527 508-865-9998 
Doss Plastics, Inc. 94 Ashland Ave. Southbridge, MA 01550 508-764-3211 
Eac       
East Acres Farms Inc.  236 Blackmer Rd. Southbridge, MA 01550 508-765-0535 
Eastwest Pharmaceutical 
International 33 Hemingway St Shrewsbury, MA 01545 508-791-8544 
ECI Biotech, Inc 85 Prescott Street Worcester, MA 01605 508-752-2209 
Eden Research plc       
Emuge Corporation 1800 Century Dr 
West Boylston, MA 
01583 508-595-3619 
Entegrion Inc.       
EpigenDX 15 Harris Ln Ashland, MA 01721 508-881-6810 
Filtrona Extrusion Inc 170 Bartlett St Northborough, MA 01532 508-393-2553 
Fisher Scientific 8 Forge Pkwy Franklin, MA 02038 508-553-5000 
Funnel Insruments LLC 79 Hecla St Uxbridge, MA 01569 508-278-0800 
Gene-IT 25 Winthrop Street Worcester, MA 01604 508-754-7300 
Genetex Optics Inc 183 West Main Dudly, MA 01571 508-943-3860 
Genzyme Genetics  3400 Computer Drive Westborough, MA 01581 508-898-9001 
GLSynthesis, Inc  One Innovation Drive Worcester, MA 01605 508-845-9484 
GlucaDel Consulting       
GlycoSolutions, Corp. 25 Winthrop Street Worcester, MA 01604 508-756-6418 
Gyrus Acmi 136 Turnpike Road Southborough, MA 01772 508-8042600 
Hematech 377 Plantation St. Worcester, MA 01605 508-792-0682 
Hightech Precision Moulders LLC 30 Patriots Circle Leominster, MA 01453 978-534-5000 
Hypnion Inc  381 Plantation Street Worcester, MA 01605 508-438-2800 
Hypromatrix, Inc. 100 Barber Ave Worcester, MA 01606 508-856-7900 
Imaging Diagnostics, Inc. 98 Pratts Junction Rd Sterling, MA 01564 978-422-8601 
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Imaging Diagnostics, Inc. 99 Pratts Junction Rd Sterling, MA 01565 978-422-8602 
Indigene Pharmaceuticals, Inc.  115 Flanders Rd. Westborough, MA 01581 508-389-1701 
Infonetics Corp. 2 Flint Meadow Ln. Shrewsbury, MA 01345 508-845-9824 
Informatics & Computing 
Resources Center       
Infussafe 13 Massachusetts Ave Harvard, MA 01451 978-805-3183 
Innovend 30 Patriots Cir Leominster, MA 01453 978-534-5000 
Insight Neuroimaging Systems, 
LLC 111 Canterbury St Worcester, MA 01610 508-799-6464 
Integrated Pharmaceuticals Inc 310 Authority Dr Fitchburg, MA 01420 978-696-0020 
JR Medical Technology 123 Briar Wood Ave Southbridge, MA 01550 508-764-2121 
Kinefac Corp 156 Goddard Memorial Drive Worcester, MA 01603 508-754-6891 
Laser Therapeutics Inc 101 Waterside Dr Centerville, MA 02632 508-790-9300 
Latham Laboratories Inc 
Worcester Biotechnology 
Park Worcester, MA 01605   
Lex Company 178 Lincoln Street Worcester, MA 01605   
LINOS Photonics, Inc. 459 Fortune Blvd. Milford, MA 01757 508-478-6200 
Liporx Pharmaceuticals Inc One Innovation Drive Worcester, MA 01605   
Luxtec Corporation 326 Clark St. Worcester, MA 01606 508-856-9454 
Mar-lee Companies 190 Authority Dr Fitchburg, MA 01420 978-343-9600 
Mar-lee Companies, Inc 180 Authority Dr Fitchburg, MA 01420 978-348-1291 
Mass Biotechnology Research Park One Innovation Drive Worcester, MA 01605 508-755-2230  
Mass Histology Service 31 Huron Ave Worcester, MA 01605 508-853-9363 
Massachusetts Biomedical 
Initiatives  60 Prescott Street Worcester, MA 01605 508-797-4200 
Mass Micro Laboratories, Inc.  25 Winthrop Street Worcester, MA 01604 508-752-0858 
Medcon Biolab Technologies 50 Brigham Hill Rd Grafton, MA 01519 508-839-4203 
Medical Equipment Specialists Inc 14 Lake Ave Worcester, MA 01604 508-757-3390 
Microbiotix Inc  One Innovation Drive Worcester, MA 01605 508-757-2800 
Micron  Products Inc 25 Sawyer Passway Fitchburg, MA 01420 978-345-5000 
Miniature Tool & Die, Inc. 15 Trolley Crossing Rd Charlton, MA 01507 508-248-0111 
Mossman Associates Inc 9 Village Cir Milford, MA 01757 508-488-6169 
Mtm Laboratories Inc 134 Flanders Rd Ste 325 Westborough, MA 01581 508-366-8334 
Netoptix Corp 
PO Box 550, Sturbridge 
Buisness Park Sturbridge, MA 01566 508-347-9191 
New England Peptide Inc  65 Zub Lane Gardner, MA 01440 888-343-5974 
New World Laboratories 25 Winthrop Street Worcester, MA 01604   
News Technical Gases 31 Sword Street Auburn, MA 01501 508-791-9293 
NOVAGENESIS 
One Innovation Drive, 
Biotech III Worcester, MA 01605 508-797-6682 
NP Medical, Inc. 101 Union Street Clinton, MA 01510 978-365-2500 
NuGenesis Technologies 
Corporation 1900 West Park Drive Westborough, MA 01581 508-616-9876 
Oliver M Dean Inc 125 Brooks St Worcester, MA 01606 508-856-9100 
Omega PharmServices, Inc.  113 Cedar St. Suite S-6 Milford, MA 01757 508-482-9330 
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OPCO Laboratory Inc 704 River Street Fitchburg, MA 01420 978-345-2522 
OPTIM, Inc. 64 Technology Park Road Sturbridge, MA 01566 800-225-7486 
Optimum Technologies, Inc. 68 West Street Southbridge, MA 01550 508-765-8100 
Pgm Plastics Inc 774 Crawford St Fitchburg, MA 01420 978-342-6767 
Pharm Development Consulting       
Physical Research 
451 Worcester Road; Route 
20 Charlton, MA 01507 508-865-9103 
Phytera Inc 377 Plantation Street Worcester, MA 01605 508 792-6800 
Plant Pharmaceuticals Inc One Innovation Drive Worcester, MA 01605   
PolyCarbon Industries, Inc. 435 Lancaster Street Leominster, MA 01453 978-772-2111 
PolyOrg, Inc. 10 Powers Street Leominster, MA 01453 978-466-7978 
Precision Optics Corporation 22 E Broadway Gardner, MA 01440 978-630-1800 
ProFoldin       
Pyrosequencing Inc  
2200 West Park Drive, Suite 
320 Westborough, MA 01581 508-389-9911 
Q-One Biotechnologies, Ltd. 381 Plantation Street Worcester, MA 01604 508-791-8000 
Radius Product Development 200 Union St Clinton, MA 01510 978-368-3200 
REM Inc       
RenalPlant Corporation 5 Leonard Drive Southborough, MA 01722 508-624-0150 
RES-TECH Corporation 22 Marshall Street Clinton, MA 01510 978-368-0146 
Rocheleau Tool & Die Co Inc 117 Industrial Rd Fitchburg, MA 01420 978-345-1723 
RXi Pharmaceuticals Corporation 1 Innovation Drive Worcester, MA 01605 508-767-3861 
Saint-Gobain Abrasives Inc. 1 New Bond St. Worcester, MA 01606 508-795-5000 
Schott Fiber Optics, Inc 122 Charlton Street Southbridge, MA 01550 800-343-6120 
Seatech Bioproducts Corp 159 Memorial Drive; Unit C Shrewsbury, MA 01545 508-842-9292 
Select Engineering Inc 260 Lunenburg St Fitchburg, MA 01420 978-345-4400 
SelectX Pharmaceuticals, Inc. 
One Innovation Drive, 
Biotech III Worcester, MA 01605 508-798-0216 
SeraCare Diagnostics  25 Birch Street Milford, MA 01757 508-478-5510 
Shire Biologics Inc  30 Bearfoot Road Northborough, MA 01532 508-351-9944 
SquiCor Labs Inc. 80 Optical Drive Southbridge, MA 01550 360-450-4140 
Steelcraft 115 W. Main Street Millbury, MA 01463 508-865-4445 
Steris-Isomedix Services 435 Whitney Street Northborough, MA 01532 508-393-9323 
Stethographics Inc 21 Wayside Rd Westborough, MA 01581 508-320-2841 
Targeted Cell Therapies  60 Prescott Street Worcester, MA 01605 508-517-8400 
Techman International Corp 16B Sturbridge Road Charlton, MA 01507 508-248-2900 
Technical Innovation Center, Inc.  100 Barber Avenue Worcester, MA 01606 508-799-6700 
T M Electronics 45 Main Street Boylston, MA 01505 508-856-0500 
TranXenoGen, Inc.  800 Boston Turnpike Shrewsbury, MA 01545 508-936-4200 
Valeritas, LLC 
800 Boston Turnpike (Route 
9) Shrewsbury, MA 01545 508-845-1177 
Valmed, Inc. 221 Spring Street Shrewsbury, MA 01545 508-845-3438 
Vascular Sciences 44 Edward Drive North Grafton, MA 01536 508-887-9486 
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Verax Biomedical Incorporated  377 Plantation St, Biotech 4 Worcester, MA 01605 508-755-7029 
Viking Systems 134 Flanders Rd Westborough, MA 01581 508-366-8882 
Vista Medical Technologies 134 Flanders Road Westborough, MA 01581 508-366-3668 
VivaScan Corp. 560 Prospect St 
West Boylston, MA 
01583 508-852-1600 
Water Corporation 34 Maple Street Milford, MA 01757 508-478-2000 
Welgen, Inc.  25 Winthrop Street Worcester, MA 01604 888-493-5436 
WesaGen Inc       
Zoaan Diagnostics, Inc. 159 Memorial Drive; Unit C Shrewsbury, MA 01545 508-842-9020 
 
